Clinical and Immunological Studies in Patients with Atypical Mycobacterial Isolations by Kotilainen, Hannele
Department of Medicine
Division of Infectious Diseases
Inflammation Center
Helsinki University Central Hospital
Helsinki, Finland
CLINICAL AND IMMUNOLOGICAL 
STUDIES IN PATIENTS WITH ATYPICAL 
MYCOBACTERIAL ISOLATIONS
Hannele Kotilainen
ACADEMIC DISSERTATION
To be publicly discussed with the permission of  
the Medical Faculty of the University of Helsinki, in the Auditorium 4,  
Meilahti Hospital, Haartmaninkatu 4, Helsinki, on 30th, 2015, at 12 noon.
Helsinki 2015
Supervisor
Docent Asko Järvinen MD, PhD
Department of Medicine, Division of Infectious Diseases
Inflammation Center
Helsinki University Central Hospital 
Helsinki, Finland
Reviewers
Docent Esa Rintala, MD, PhD
Department of Medicine, Division of Infectious Diseases
Turku University Hospital 
Turku, Finland
Docent Hannu Syrjälä, MD, PhD
Department of Infection Control
Oulu University Hospital 
Oulu, Finland
Opponent
Docent Risto Vuento, MD, PhD
Microbiology, Fimlab Laboratories PLC
Tampere University Hospital
Tampere, Finland
ISBN 978-951-51-1619-2 (pbk)
ISBN 978-951-51-1620-8 (pdf)
Unigrafia
Helsinki 2015
To my family
 
CONTENTS
LIST OF ORIGINAL PUBLICATIONS ..............................................................8
ABBREVIATIONS .............................................................................................9
ABSTRACT  ......................................................................................................10
1 INTRODUCTION  .....................................................................................12
2 REVIEW OF THE LITERATURE ............................................................. 14
2.1 NTM mycobacteria ............................................................................ 14
2.1.1 Non-tuberculous mycobacteria (NTM) species  ..................... 14
2.1.2 Characteristics of mycobacteria .............................................. 14
2.1.3 NTM species and their classification ...................................... 15
2.2 Epidemiology  .................................................................................... 16
2.2.1 NTM are ubiquitous in the environment ................................ 16
2.2.2 NTM transmission into human and animals .......................... 17
2.2.3 Geographical distribution  ......................................................18
2.2.4 Incidence and prevalence of NTM  ........................................ 20
2.3 Risk factors for NTM infections in immunocompetent persons  .... 20
2.3.1 Age and gender ....................................................................... 20
2.3.2 Underlying pulmonary diseases  ............................................. 21
2.3.3 Other underlying diseases relative risk factors ......................22
2.4 Pathogenesis  .....................................................................................23
2.4.1 Genetic susceptibility to NTM .................................................25
2.5 Clinical manifestations  .....................................................................27
2.5.1 Pulmonary NTM infections .................................................... 28
2.5.2 Extrapulmonary NTM infections ............................................ 31
2.5.3 Disseminated NTM infection in immunocompromised  
patients  ...................................................................................32
2.5.4 Health care related NTM infections  .......................................34
2.6 Diagnosis of NTM infection ...............................................................35
2.6.1 Laboratory diagnosis of NTM .................................................35
2.6.2 Diagnostic ATS criteria ...........................................................35
Contents
2.7 Treatment of NTM infections ............................................................39
2.7.1 Treatment of NTM among immunocompetent patients ........39
2.8 Prognosis of NTM infection ...............................................................42
2.8.1 Prognosis of pulmonary NTM infection .................................42
2.8.2 Prognostic factors in pulmonary NTM infection ....................42
2.8.3 Prognosis of disseminated NTM infection .............................43
3 AIMS OF THE STUDY ..............................................................................44
4 MATERIALS AND METHODS .................................................................45
4.1 Patients (Study I–IV) .........................................................................45
4.2 Ethics ..................................................................................................47
4.3 Data collection  ..................................................................................47
4.4 Definitions  .........................................................................................50
4.4.1 NTM infection and disease according to ATS criteria 2007 .....50
4.4.2 C4 deficiency analyses  ............................................................ 51
4.4.3 Radiological findings ............................................................... 51
4.4.4 Laboratory findings ................................................................. 51
4.5 Microbiological methods ................................................................... 51
4.5.1 Identification of mycobacteria ................................................ 51
4.5.2 Identification of C4 deficiency ................................................52
4.5.3 Identification of low immunoglobulin levels ..........................52
4.6 Statistical methods .............................................................................52
5 Results  ......................................................................................................54
5.1 Demographic characteristics of patients with  
a NTM isolation (I–III)  .....................................................................54
5.2 Underlying diseases among patients with a NTM isolation (I–III) ... 56
5.3 Symptoms at the time of NTM isolation (I–III) ...............................58
5.4 Microbiological findings (I-III) ........................................................ 60
5.5 Radiological findings (I–III)..............................................................62
5.6 Prognostic factors ..............................................................................64
5.6.1 Smoking as a prognostic factor (I) ..........................................64
5.6.2 ATS 2007 criteria as a prognostic factor (II) ..........................64
5.6.3 Anti-mycobacterial medication as a prognostic factor (II) ......64
5.6.4 MAC as a prognostic factor (III)  ............................................65
5.7 Complement C4 and immunoglobulin levels in NTM and  
MTB patients (IV and unpublished results of MTB patients) ..........67
5.7.1 NTM and MTB patient characteristics and  
mycobacterial strains ..............................................................67
5.7.2 Complement analyses .............................................................70
5.7.3 Immunoglobulin concentrations and other  
laboratory measurements .......................................................72
6 DISCUSSION  ............................................................................................73
6.1 General discussion .............................................................................73
6.2 Risk factors for NTM infection  .........................................................74
6.2.1 Smoking as a risk factor for NTM infection ............................74
6.2.2 Age and gender as risk factors for NTM infection ..................75
6.2.3 Previous pulmonary diseases as a risk factor for  
NTM infection .........................................................................76
6.2.4 Severe underlying diseases as risk factors for  
NTM infection .........................................................................77
6.2.5 C4 deficiency as a risk factor for NTM infection ....................78
6.3 Prognostic factors in NTM infections ............................................... 80
6.3.1 Smoking as a prognostic factor .............................................. 80
6.3.2 ATS criteria as a prognostic factor ..........................................81
6.3.3 NTM strain as a prognostic factor ......................................... 82
7 SUMMARY AND CONCLUSIONS ............................................................85
8 ACKNOWLEDGEMENTS  ....................................................................... 86
9 REFERENCES .......................................................................................... 88
ORIGINAL PUBLICATIONS .........................................................................105
8LIST OF ORIGINAL PUBLICATIONS
The thesis is based on four original publications, referred to in the text by their 
Roman numerals I–IV:
I Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Järvinen A. Clinical 
symptoms and survival in non-smoking and smoking HIV-negative patients 
with non-tuberculous mycobacterial isolation. Scand J Infect Dis 2011;43:188–
196.
II Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Järvinen A. 
Prognostic value of American Thoracic Society criteria for non-tuberculous 
mycobacterial disease: A retrospective analysis of 120 cases with four years of 
follow-up. Scand J Infect Dis 2013;45:194–202.
III Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Järvinen A. Clinical 
findings in relation to mortality in non-tuberculous mycobacteria infections 
patients with Mycobacterium avium complex have better survival than patients 
with other mycobacteria. Eur J Clin Microbiol Infect Dis 2015;34:1909–1918, 
DOI 10.1007/s10096-015-2432-8.
IV Kotilainen H, Lokki M-L, Paakkanen R, Seppänen M, Tukiainen P, Meri S, 
Poussa T, Eskola J, Valtonen V, Järvinen A. Complement C4 deficiency – a 
plausible risk factor for non-tuberculous mycobacteria (NTM) infection in 
apparently immunocompetent patients. PLoS ONE 2014;9(3): e91450. 
The original publications are reprinted with the permission of the copyright holders.
9ABBREVIATIONS
AIDS acquired immunodeficiency syndrome
ATS American Thoracic Society
AFB acid fast bacilli
BCG bacillus Calmette-Guérin
BMI body mass index, kg/m2 
C4 complement component 4
C4A acidic isotype of complement component 4
C4B basic isotype of complement component 4
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COPD chronic obstructive pulmonary disease
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Abstract 
ABSTRACT 
Non-tuberculous mycobacteria (NTM) have become more common than 
M. tuberculosis (MTB) in many countries. NTM are ubiquitous and all people are 
exposed to them but only a few people may catch a NTM infection. Most infections 
due to NTM are pulmonary, thereafter cutaneous and disseminated infections and 
some NTM strains may cause lymphadenitis. The most common NTM strain in 
clinical samples is Mycobacterium avium complex (MAC) which is responsible for 
more than half of clinical cases. 
The reasons why some people will develop a clinical NTM disease are still poorly 
known. Chronic lung-disease patients and non-smoking healthy elderly females have 
been described as the main risk groups. NTM infections are common opportunistic 
infections in acquired immunodeficiency syndrome (AIDS) patients. Rare genetic 
defects with disseminated NTM infection have also been described in families. 
Immunological defects behind pulmonary NTM infections have not been found 
except a local defect in nitric oxide production and ciliary beat of airway epithelium. 
In this doctoral thesis, the underlying factors and clinical picture of NTM 
infections in Finland have been studied. The clinical picture and smoking as a 
risk factor for NTM infection have been investigated in Study I. The American 
Thoracic Society (ATS) has published criteria to discern patients with a clinical 
disease from those of airway colonization with NTM. The prognostic value of these 
criteria has been studied (II). The clinical picture and prognosis of patients infected 
with MAC has been compared to patients with other NTM infections (III). Genetic 
susceptibility to pulmonary tuberculosis has been linked to major histocompatibility 
complex (MHC) class I, II and III regions on chromosome 6p21.3. The complement 
system has a host defense role in innate immunity, thus deficiencies of complement 
components C4A or C4B that are encoded by major histocompatibility complex 
(MHC) were studied in NTM and tuberculosis patients (IV).
 
Materials and methods. Altogether 120 adult non-HIV patients with at least 
one NTM isolation during 1990–1998 were included in Studies I and II. Their 
symptoms, clinical findings, comorbidities, laboratory findings, medical therapy, 
and survival were retrieved from medical records comprising at least four years 
to 8th June 2006. The patients were classified as smokers or never smokers and 
categorized according to fulfillment of ATS 2007 criteria. In study III, 167 patients 
with at least one positive NTM isolation including patients from Studies I–II and 
IV were included and data was retrieved as described above. Study IV consisted 
of 50 adult NTM patients and 31 patients with MTB infection who were admitted 
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to hospital between August 2004 and December 2009. Their clinical picture was 
retrieved and they gave blood samples for analysis of C4A and C4B genotype and 
phenotype frequencies of the C4 allotypes, serum immunoglobulin, and complement 
levels. Controls were comprised of 149 healthy, unselected Finnish people. 
Results. Overall 42% of patients had never smoked. In the group of non-smokers, 
72 % were female, while in the group of smokers, only 30% of smokers were female 
(I). MAC comprised 72% of isolates among non-smokers and 41% among smokers. 
No potentially fatal underlying diseases were found in 82% of non-smokers but 
only in 59% of smokers. Smokers had higher risk of mortality than non-smokers 
but no difference was observed after adjusting for underlying diseases. Symptoms 
had started within a year of positive NTM isolation in 48% of patients suggesting 
rapid development of symptoms. Only half of patients with a NTM isolation fulfilled 
the 2007 ATS criteria. ATS positive cases were, more often, female and had less 
frequent fatal underlying diseases as compared to ATS-negative cases. No significant 
difference was seen in median survival time or symptoms between ATS-positive and 
-negative cases except in fatigue which was more common in ATS-positive patients. 
ATS criteria fulfillment was a weak prognostic marker. MAC was isolated in 59% of 
cases and MAC patients were more often female, had more frequent bronchiectasis, 
and presented fewer fatal underlying diseases than patients with other NTM. There 
was no difference in ATS 2007 criteria fulfillment between MAC and other NTM 
patients. The other NTM patients (54%) had suffered from symptoms less than a 
year as compared to MAC patients (34%). MAC patients had significantly lower 
risk of death and longer survival time than other NTM patients. Finnish NTM 
patients (72%) had significantly more frequent C4 deficiencies (C4A or C4B) as 
compared to unselected healthy control subjects (56%) and MTB (35%). Especially, 
C4 deficiencies were common in female NTM patients (81%) as compared to female 
controls (55%). 
Conclusion. Smokers and non-smokers had different risk factors for NTM 
infection. ATS 2007 criteria had a weak prognostic value in finding patients with 
risk of fatal outcome. Patients with MAC had a longer survival than patients with 
other NTM. About half of the patients had suffered from symptoms for less than 
a year, suggesting a more rapid disease progression than previously emphasized. 
Complement C4 deficiency may be a risk factor for NTM infection, especially in 
elderly female patients. 
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1 INTRODUCTION 
The genus mycobacterium is assumed to have originated over 150 million years ago. 
Mycobacterium tuberculosis (MTB) is the best known representative of this genus. 
Tuberculosis (TB) was documented in Egypt more than 5000 years ago. Typical 
skeletal abnormalities of tuberculosis, including characteristic Pott’s deformities in 
bones, have been found in Egyptian mummies (Daniel 2006).
The disease caused by M. tuberculosis was well known in classical Greece, where 
it was called “phthisis”. Hippocrates clearly recognized tuberculosis and understood 
its clinical presentation (Daniel 2006). TB reached epidemic proportions in Europe 
and North America during the 18th and 19th centuries (Daniel 2006). 
Tuberculosis also played a major role in the development of modern microbiology. 
In 1882, Robert Koch made his famous presentation on the etiology of tuberculosis 
to the Berlin Physiological Society. Koch demonstrated the tubercle bacillus which 
he had identified and posted at the same time as his famous postulates. Koch`s 
four postulates established a causal relationship between a microorganism and 
a disease and also provided a basis for describing microbes as pathogens, which 
led to the development of modern infectious and communicable diseases etiology 
(Fredriks and Relman 1996).
Even today, tuberculosis (TB) remains one of the world’s deadliest communicable 
diseases. In 2013, the World Health Organization (WHO) estimated that 9.0 million 
people developed TB and 1.5 million died from the disease (WHO 2014).
Late in the 19th century, it was recognized that a micro-organism different from 
Mycobacterium tuberculosis (MTB) caused “tuberculosis” in chickens (Thorel et al. 
1997). This micro-organism was later shown to be Mycobacterium avium. It was 
first thought that it would not cause disease in humans but during the 1950s, M. 
avium was demonstrated to be able to act as a human pathogen (Wolinsky 1979). 
Since the 1950s new mycobacteria have been characterized with increasing speed 
(Wolinsky 1979, Brown-Elliot et al. 2010). 
The term “atypical mycobacteria” originated from the earlier belief that they 
were unusual compared to M. tuberculosis (Falkinham 1996). As understanding 
of mycobacteria grew, those less pathogenic “mycobacteria other than tuberculosis 
(MOTT)” were found to be ubiquitous in the environment; in natural waters, 
drinking waters, and soils (Falkinham 1996). Thus, a new term “nontuberculous 
mycobacteria” was created and it included those mycobacterial species that were not 
members of the Mycobacterium tuberculosis complex (M. tuberculosis, M. africae, 
M. bovis) or M. leprae. When it became well-known that M. tuberculosis could be 
transmitted through aerosols from person to person, infection of NTM proved to 
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be acquired from environment by the inhaled aerosolized droplets containing NTM 
or exposure to them through to skin abrasions (Falkinham 1996). Pulmonary NTM 
infections were first related to pre-existing pulmonary diseases or heavy occupational 
exposure to them as was seen in gold miners (Maliwan et al. 2005). However, more 
than 35 years ago they were found to cause disease in previously healthy persons, 
often females, as well (Prince et al. 1989, Kubo et al.1998, Huang et al. 1999).
The clinical importance and interest in NTM exploded when they were observed 
as one of the most important opportunistic infections in patients with Acquired 
Immune Deficiency Syndrome (AIDS) (Lowell et al.1986, Horsburgh et al. 2001). 
NTM infections associated to human immunodeficiency virus (HIV) profoundly 
revealed the pathogenic potential of nontuberculous mycobacteria (Benson and 
Ellner 1993). Simultaneously, however, the focus of NTM disease was changed to 
severely immunosuppressed patients. In HIV patients, NTM and mainly M. avium 
caused a disseminated disease first when the cell-mediated immune response was 
severely affected (Benson and Ellner 1993). The mechanisms of disseminated NTM 
infection were revealed but the interest in NTM infections in immunocompetent 
people was halted for almost 30 years. In Finland, NTM infections have been 
less studied, yet the number of publications on NTM infections has increased 
dramatically over the last years in Scandinavia, Europe and Asia. 
The incidence of TB is slowly declining each year and it is estimated that 37 
million lives were saved between 2000 and 2013 through effective diagnosis and 
treatment (WHO 2014). However, over 120 new species of mycobacteria have been 
discovered and advances have been made in diagnosis and treatment (Falkinham 
2010). Further, the incidence of NTM isolations has been increasing in many 
countries (Cassidy et al. 2009, Andréjak et al. 2010, Marras et al. 2013). In Finland, 
the annual incidence of all NTM isolations has increased between 1995–2014 from 
6.45/ 100 000 person-years to 11.98/ 100 000 person-years (National Institute 
for Health and Welfare, National Infectious Disease Register in Finland 2015). 
Concurrently, the incidence of tuberculosis in Finland has decreased from 12.93/ 
100 000 person-years in 1995 to 4.42/ 100 000 person-years in 2014 (National 
Institute for Health and Welfare, National Infectious Disease Register in Finland 
2015).
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2 REVIEW OF THE LITERATURE
2.1 NTM MYCOBACTERIA
2.1.1 NON-TUBERCULOUS MYCOBACTERIA (NTM) SPECIES 
Mycobacterium is the only genus in the family Mycobacteriaceae, which consists of 
over 120 species (Tortoli 2006). The more pathogenic group entails Mycobacterium 
tuberculosis complex, which consists of eight subgroups (M. tuberculosis, M. bovis, 
M. africanum, M. microti, M. canettii, M. caprae, M. pinnipedii, M. mungi) and M. 
leprae which was found in mammals (Maartens and Wilkinson 2007, van Ingen et 
al. 2012). However, various mycobacteria have later been found in environmental 
sources, most abundantly in aqueous spaces (Falkinham 1996). Most of these 
environmental NTM species have been discovered since 1950 (Wolinsky 1979).
Only 10 NTM species were known in 1948 (Griffith et al. 2002). The speed of 
detection of new species seems to be increasing, because 42 new NTM species have 
been detected from clinical samples since 1990 (Tortoli 2003). Thereafter, only 28 
NTM species have been identified during the years 2003–2006 (Tortoli 2006). 
Out of 120 presently characterized NTM species, approximately 60% are probably 
connected to disease in humans (Tortoli 2006).
2.1.2 CHARACTERISTICS OF MYCOBACTERIA
Mycobacteria are aerobic, straight, germless rods (Brennan and Nikaido 1995), 
which possess a cell wall with a high lipid content; up to 60–70% of cell wall 
weight. The cell wall is held together by three layers of macromolecules: a mycolic 
acid containing layer, a polysaccharide layer with arabinogalactan, and an inner 
peptidoglycan layer in connection with the cell membrane (Brennan and Nikaido 
1995, Daffe et al. 1998). High lipid content makes the cell wall highly hydrophobic 
and protects mycobacteria against phagocytosis and even against physical stress 
like acid, alcohol, heavy metals and antimycobacterial medication (Falkinham 
2010). The cell wall impermeability constitutes one of the main characteristics of 
mycobacteria; they are acid-fast and capable of intracellular living (Primm et al. 
2004). These common characteristics make NTM and Mycobacterium tuberculosis 
indistinguishable in microscopic appearance where they both are characterized as 
gram-positive rods and they also are indistinguishable in acid-fast (Ziehl-Neelsen) 
stain (Woods 2002).
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Several physiologic characteristics contribute NTM to overcome in nature. 
Mycobacteria are considered obligate aerobes but numbers of microaerophilic 
mycobacteria have been isolated from low-oxygen habitats (Falkinham 2010). 
NTM grow in acidic environments with pH values 5.0–6.5 and there is only little 
growth in alkaline environments, where pH is above 7.5. Most NTM are able to 
grow in temperatures ranging from 10°C to 45°C (Falkinham 2003). In nature NTM 
grow in fresh, brackish, and salty water (Falkinham 2003). Most NTM species are 
thermoresistant and some species like M. avium, M. intracel lulare, M. scrofulaceum, 
and M. xenopi have consider ably higher resistance in hot water heaters than 
Legionella pneumophila (Falkinham 2010). The most heat resistant species, M. 
xenopi, has been associated with epidemics through hot water distribution systems 
(Brown-Elliot 2002, Falkinham 2010). In contrast, low temperatures are optimal to 
NTM species that cause skin infections like M. marinum (optimal growth at 30°C) 
and M. haemophilium (32 °C) (Falkinham 2010).
The growth of NTM in environmental reservoirs even low in organic matter is a 
result of metabolic characters of NTM. They are able to use carbon and nitrogen for 
nutrition (Falkinham 2010). Further, mycobacteria are able to degrade hydrocarbon 
pollutants even in clean water sources, which are used for drinking water (Primm 
et al. 2004). Moreover, the hydrophobicity and impermeability of cell membranes 
protect NTM in the environment. Conversely, the slow growth rate and delayed 
metabolism represent disadvantages (Primm et al. 2004). Biofilm formation 
supports growth and persistence in nature but increases the virulence of NTM in 
foreign bodies like vascular catheters of patients (Falkinham 2010).
2.1.3 NTM SPECIES AND THEIR CLASSIFICATION
Since the 1950s, NTM have been categorized into four types based on their growth 
rate and pigmentation (Timpe and Runyon 1954) (Table 2.1.3). According to this 
classification, types I, II, III grow slowly in culture over 7 days whereas type IV 
grows in less than 7 days. Further, these types were classified according to their 
colony pigmentation (Table 2.1.1).
16
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Table 2.1.3. NTM classification according to Timpe and Runyon based on NTM growth and colony pigment 
formation. Modified according to: Yeager and Farah 2006, Wallace Jr 1994
Group Morphology Examples
I
Photochromogens Producing pigment on exposure 
to light
M. kansasii, M. marinum
II
Scotochromogens Producing pigment in the dark M. scrofulaceum,
M. gordonae
III
Nonchromogens Producing no pigment M. avium complex,
M. malmoense,
M. nonchromogenicum
IV
Rapid growers Grows in less than 7 days and any 
of the above pigment types
M. abscessus, M. fortuitum, M. 
chelonae
Due to the development of genetic techniques, several new species of both slowly 
and rapidly growing NTM have been found during 1990–2000. Many of these 
NTM species were found from clinical human samples but were not found in the 
environment (Brown-Elliot 2002, Tortoli 2003).
2.2 EPIDEMIOLOGY 
2.2.1 NTM ARE UBIQUITOUS IN THE ENVIRONMENT
Reservoirs of NTM are natural and municipal water sources, soil, food, protozoans, 
and other animals (Falkinham 2002, Primm et al. 2004). NTM have also been 
recovered from potting soils and even cigarettes (Eaton et al. 1995, Falkinham 
2002). Aqueous environments are the main source of NTM and they have been 
isolated from lakes and ponds and especially from acid brown-water swamps in 
USA and peat land in Finland (Falkinham 2002). In Finland during 1990–1993, 
mycobacterial species were measured from brook waters and collected from 53 
drainages located in a linear belt crossing Finland at 63° (Iivanainen et al. 1993). 
The majority of environmental isolates represented unknown mycobacterial species, 
but 15% of the isolated species were also common in human infections like M. 
avium, M. avium complex, M. scrofulaceum, M. branderi, M. terrae, M. gordonae, 
M. xenopi (Iivanainen et al. 1993, Torkko et al. 2003). MAC, M. kansasii, M. 
malmoense, M. xenopi, and RGM have been found from drinking water, and MAC 
has been discovered also in public bath water, hospital water, and water supplies 
of hemodialysis centers (Falkinham 2002). No NTM has been found in ground 
water and bottled water, however (Falkinham 2010, Mello 2013). NTM may escape 
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water filtration and they are resistant to chlorine and biocides (Falkinham 2002). In 
hospitals, NTM resistant to disinfectants have been recovered in instruments and 
in contaminated bronchoscopes (Falkinham 2002). Similarly, in household water 
and plumbing, M. avium and M.intracellulare may be concentrated in biofilm 
(Falkinham 2010, Mello 2013). 
NTM have rarely been found in food but they may be found, for example, in 
vegetables and eggs. However, raw milk samples have been reported to contain 
M. kansasii, M. avium, M. intracelluare, and M. fortuitum (Falkinham 2002). 
Environmental exposure to NTM may lead to disease pictures distinct from classical 
infections. 
2.2.2 NTM TRANSMISSION INTO HUMAN AND ANIMALS
NTM are opportunistic pathogens of humans and animals, with variable virulence 
and geographical distribution (Falkinham 2002, Primm et al. 2004). In nature, 
MAC may live in symbiosis with amoebae, which may increase its virulence (Cirillo 
et al. 1997). Various NTM have been isolated from wild and domestic animals, 
e.g. macaques and mesenteric lymph nodes of pigs (Falkinham 2002). M.avium, 
M.fortuitum, and M.genavense have been recovered from birds (Falkinham 2002).
M. tuberculosis is a known airborn disease, where the aerosol transmission occurs 
from person to person. In contrast, infection of NTM is assumed to be acquired 
from the environment by inhaled aerosolized droplets, ingestion or exposure to skin 
abrasions (Falkinham 1996). In that way inhaled shower water droplets may create 
airborn exposure leading to respiratory NTM diseases (Wallace et al.1997). M. avium 
has been isolated from water and also from biofilm sedmiment of showerheads 
(Falkinham 2007), which may support NTM transmission via shower droplets. The 
transmission of NTM is not well defined, however, because both environmental 
exposure and the host defense may be the major factor (Dirac et al. 2012). 
The evidence of human-to-human or animal-to-human transmission has not 
been discovered (Griffith et al. 2007). Even NTM is suspected to be acquired from 
the environment by airway exposure or by ingestion; however, the specific source of 
infection in individual cases cannot usually be identified (Wallace et al.1997, Criffith 
et al. 2007). In addition, regional differences also appear to exist in distribution 
of mycobacteria in household water systems according to a study in Japan (Ichijo 
et al. 2014).
Cervical lymphadenitis in children at age 1–5 years is caused by NTM, probably 
due to childrens habitual contact with natural water (Falkinham 2003) or ingestion 
of soil (Griffith et al. 2007). Ingestion may be an important infection route also 
in patients with AIDS related lymphadenitis or disseminated M. avium, which 
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are thought to arise through gastrointestinal colonization (Wallace et al.1997). M. 
avium in drinking water has been proved to cause infections in AIDS-patients and 
high incidence of M. avium infection in Finnish AIDS patients correlated with the 
concentration of M. avium in their household drinking water (von Reyn et al.1993).
Some mycobacteria cause mainly cutaneous infections through transmission 
via small cutaneous erosions. Fishing and aquaculture may lead to exposure to M. 
marinum. A potter may be exposed to MAC through skin abrasion. Leisure activities 
like gardening or peat-rich potting soils may lead exposure to NTM through the 
skin wounds (Falkinham 2002).
2.2.3 GEOGRAPHICAL DISTRIBUTION 
Various NTM species are observed in geographically different locations, however 
MAC is the most frequently isolated species in pulmonary infections worldwide 
(Field et al. 2006).
In Australia, up to 91% of non-HIV pulmonary NTM diseases are reported to 
be caused by MAC (OBrien 2003). In USA, MAC was responsible for 80% of NTM 
cases in New York and Portland (Bodle et al. 2008, Cassidy et al. 2010). In France, 
among 262 HIV-negative patients with NTM lung disease, 80% was caused by MAC 
(Dailloux et al. 2006). In Asia, MAC caused over 43% and in Japan up to 81% of 
pulmonary lung diseases (Simons and van Ingen 2011).
In Europe, M. xenopi has been the second after MAC as a cause of lung disease 
in France, the Netherlands and Italy and in the south-east United Kingdom (Cook 
2010). In Ontario, Canada, M. xenopi is common but it is rarely found in the USA 
(Varadi and Marras 2009, Marras et al. 2007). 
In northern Europe, M. malmoense has been reported to be the second after 
pulmonary MAC in Sweden (Petrini et al. 2006), in Finland (Katila and Brander 
1991), and in Scotland (Russel et al. 2014). Interestingly, M. malmoense was initially 
the fourth most common species after MAC in Denmark (Thomsen et al. 2002, 
Andréjak et al. 2010). M. malmoense has been found in the Netherlands, Italy 
(Tortoli 1997), and the UK (Henry et al. 2004), but it is rare in the USA (Butcholds 
et al. 1998, Cook 2010). 
M. kansasii pulmonary diseases have been found as the second most 
common species after MAC in the Central USA (Bloch et al. 1998), South 
America (Mello et al. 2013), England, Wales, and France (Dailloux et al. 
2006, Cook 2010). Moreover, among South African miners, M. kansasii has 
accounted for 68% of isolates in pulmonary infections (Corbetta et al. 1999). 
In Asia, RGM have been described to be equally clinically relevant as MAC species 
during 1971–2007 (Simons and van Ingen 2011). M. abscessus has caused 35%, M. 
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chelonae 31%, and M. fortuitum 3%, of pulmonary NTM infections in Asia (Simons 
and van Ingen 2011). However, in some regions in Asia, like in India, Taiwan, and 
South Korea, RGM have caused more than 30% of pulmonary NTM infections 
(Simons and van Ingen 2011).
Most recent laboratory data comes from NTM-Network European Trials Group 
(NET) that reported the prevalence of NTM isolations in the world in 2008. 
Altogether 30 countries from six continents participated in the study (Hoefsloot 
et al. 2013). In Europe and in Scandinavia, MAC represented 67%–33% of all NTM 
pulmonary isolations. Moreover, MAC constituted 50%–70% of all NTM respiratory 
isolations in the world. Other NTM strains in clinical findings were all clearly less 
common (Hoefsloot et al. 2013). Table 2.2.3.
Table 2.2.3. NTM geographical distribution. Modified according to Hoefsloot et al. 2013. 
All NTM pulmonary isolates % in Europe (Hoefsloot et al. 2013)
MAC M. kansasii M. xenopi M. malmoense RGM M.gordonae
Finland 38 1 0 1 15 15
Sweden 67 4 0 4 12 1
Norway 55 5 2 5 15 15
Denmark 54 4 3 4 10 18
Germany 55 6 3 2 12 19
UK 22 11 10 1 44 10
Netherland 34 7 3 2 17 16
France 38 5 8 1 16 29
Italy 33 2 22 2 13 24
All NTM respiratory isolates % in the world (Hoefsloot et al. 2013)
N-America 52 1 12 rare 20 12
S-America 31 20 rare rare 20 17
Europe 37 5 14 1 16 17
Asia 50 3 rare rare 30 6
S-Africa 50 3 1 rare 7 5
Australia 70 4 rare rare 15 2
20
Review of the literature
2.2.4 INCIDENCE AND PREVALENCE OF NTM 
The incidence of NTM in clinical samples is reported to have increased during the last 
decade (Cassidy et al. 2009, Marras 2013). However, comparison of incidence rates 
is complicated by the different ways to report them. In some countries, incidence 
is given only on ATS criteria positive cases, i.e. NTM disease whereas in other 
countries incidence of NTM isolations is reported. NTM is not a notifiable condition 
in most of the European countries and in the USA. Therefore, the reported incidence 
estimates of NTM are not comparable. In Finland, NTM is notifiable. Moreover, 
the epidemiological methods (i.e. standardization) are different between studies.
Indeed, the incidence estimates vary markedly from each other in recent studies: 
0.73 cases of NTM pulmonary diseases per 100,000 person-years in France in 
2002 (Dailloux et al. 2006). In Denmark in 1997–2008, the annual incidence rate 
of at least one NTM-positive specimen was 2.44 per 100,000 person-years and 
1.36 of NTM colonization (Andréjak et al. 2010). Further, the annualized isolation 
rate in Ontario, Canada was 11.4 per 100,000 person-years in 1998 and increased 
even up to 22–25 per 100,000 person-years in 2008–2010 (Cassidy et al. 2009, 
Marras et al. 2010).
The incidence of all NTM isolates in Finland has been increased from 1995 
to 2014, from 6.45/ 100,000 person-years up to 11.98/ 100,000 person-years 
(National Institute for Health and Welfare, National Infectious Disease Register in 
Finland 2015). In contrast, the incidence of tuberculosis has been decreased from 
1995 to 2014 from 12.93/ 100,000 person-years to 4.42/ 100,000 person-years 
(National Institute for Health and Welfare, National Infectious Disease Register 
in Finland 2015).
2.3 RISK FACTORS FOR NTM INFECTIONS IN 
IMMUNOCOMPETENT PERSONS 
2.3.1 AGE AND GENDER
Pulmonary NTM infections have been predominantly described in older individuals 
and the risk for disease seems to increase along with age (Mirsaeidib et al. 2014). 
NTM disease may, however, affect at any age which was observed in the Danish 
population-based study where the age of patients with NTM isolation ranged from 
15 to 96 years (Andréjak et al. 2010). However, age of patients with NTM diseases 
of the skin and soft tissue has been variable and these infections may affect at 
any age. Notably, patients with M. ulcerans are often young adults (Piersimoni 
2012). Further immunocompetent patients with NTM lymphadenitis constitute 
children, for the most part, of day-care age (Griffith et al. 2007). Male gender and 
underlying pulmonary diseases were the first risk factors connected to NTM infection 
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(Piersimoni and Scarparo 2008, Varadi and Marras 2009). However, in the more 
previous literature the gender differences have been changed or a slight female 
predominance has been described: 59% of 634 Japanese patients with ATS positive 
pulmonary disease were female (Hyashi et al. 2012). In contrast, in the Danish 
nationwide survey on all NTM isolations a slight male predominance (55%) was seen 
(Andréjak et al. 2010). Pulmonary NTM diseases have been revealed to form two 
main groups. These groups associate to age and gender, which predispose to NTM 
infection. Notably, it has been revealed that NTM disease affects immunocompetent 
female and male differently for unknown reasons (Cassidy et al. 2009, Andréjak 
et al. 2010). Furthermore, there has been a different predominance of age and 
gender during last decades. At first, pulmonary NTM occurred predominantly in 
men until 1980 (Field et al. 2004). The men aged 60–80 years (Piersimoni and 
Scarparo 2008, Waller 2006), have been traditionally more frequent smokers, with 
destructive pulmonary and radiological findings. The treatment of outcome has 
been poor with relapsing infections (Piersimoni and Scarparo 2008).
In the second risk group, since 1990, pulmonary MAC diseases have been 
considered to demonstrate a 60% predominance for elderly women (Prince et al. 
1989, Dailloux et al. 2006, Cassidy et al. 2009). Pulmonary MAC in elderly, non-
smoker women with bronchiectasis typically ranged in age: 55–75 years (Piersimoni 
and Scarparo 2008, Field et al 2006).
The third group, both male and female, exposed by environmental or vocational 
risk factors, will recover after removal from source alone. However, this age group 
includes patients with hereditary cystic fibrosis and pulmonary MAC (Piersimoni 
and Scarparo 2008).
2.3.2 UNDERLYING PULMONARY DISEASES 
Bronchiectasis has been suggested as one of the most important risk factors, but 
also as a consequence, of pulmonary NTM infection (Fuijta et al. 2003, Field and 
Cowie 2006). Especially women with bronchiectasis and with low BMI (body mass 
index, kg/m2) have been found to be at high risk for NTM infection in both older 
and more recent studies (Prince et al. 1998, Chan and Iseman 2010, Mirsaeidi et 
al. 2013). Furthermore, elderly women with pulmonary MAC have been reported 
to have a higher incidence of bronchiectasis than other patients with pulmonary 
NTM, although they did not have underlying pulmonary diseases (Kim et al. 2008, 
Obayashi et al. 1999, Chan and Iseman 2010, Mirsaeidi et al. 2013). Pulmonary 
MAC has been thought to be a chronic, slowly-progressive disease and in the disease 
course MAC might first be a colonizing or indolent but thereafter it might gradually 
affect the lower pulmonary lobes. Persistent inflammation and mucus plugging 
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could contribute to bronchiectasis formation and both MAC and M. abscessus 
have been shown to cause bronchiectasis (Wickremasinghe et al. 2005). Chronic 
obstructive pulmonary disease (COPD) is associated with persistent inflammation 
and mucus plugging in the bronchi which could predispose to NTM infection. COPD 
and corticosteroid treatment were found to be strong risk factors for NTM disease 
due to MAC, M. kansasii, M. malmoense, and M. xenopi (Andréjak et al. 2013). 
Furthermore, COPD has been related to higher mortality in pulmonary NTM disease 
(Henry et al. 2004). 
Many other pre-existing lung diseases have been linked to increased risk for 
pulmonary NTM infection. Silicosis and coal workers pneumoconiosis have been 
linked to M. kansasii infection (Field et al. 2006). Coal workers pneumoconiosis, 
silicosis, smoking, and prior tuberculosis contribute to NTM diseases by disrupting 
the normal mucosa and contribute NTM to adhere to damaged mucosa (Middleton 
2004). Also, idiopathic pulmonary fibrosis has been associated with increased 
risk for NTM infection (Al-Anazi et al. 2014). However, it seems that the role of 
underlying pulmonary diseases might be decreasing as the proportion of women 
with pulmonary NTM but no previous pulmonary comorbidity has increased since 
the 1980s from 25% up to 70% in the last decade (Prince et al. 1989, Cassidy et al. 
2008, Kim et al. 2008).
In addition, women with NTM infection have been observed to be, in general, 
taller and leaner and 50% of them had scoliosis, 11–27% pectus excavatum, and 9% 
mitral valve prolapse (Kim et al. 2008). Due to this morphotype, it was suggested 
that they might have an associated mucociliary, immunological, or epithelial defect 
(Kim et al. 2008, Chan and Iseman 2010).
2.3.3 OTHER UNDERLYING DISEASES RELATIVE RISK FACTORS
Mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene 
might be more common among NTM patients than in the general population. 
CFTR mutations have been found in recent studies among 36–50% of pulmonary 
NTM patients (Ziedalski et al. 2006). Most of these pulmonary NTM patients were 
heterozygotes with normal sweat chloride levels and presented only mild clinical 
signs of clinical cystic fibrosis at most (Ziedalski et al. 2006, Kim et al. 2008).
Mucociliary clearance is retarded both in cystic fibrosis disease and in primary 
ciliary dyskinesia (Knowles and Boucher 2002). Fowler et al. 2013 found that 
retarded airway ciliary beat, reduced nasal nitric oxide output and a disorder in 
response to Toll- like- receptor might be risk factors to pulmonary NTM patients 
(Fowler et al. 2013). Reduced nitric oxide production could further hamper the 
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opsonization of macrophages and thereby also mycobacterial killing (Fowler et 
al. 2013).
Gastro-esophageal reflux and chronic aspiration have been related to MAC and 
M. fortuitum pulmonary diseases (Thomson 2007). However, neither Marfan’s 
syndrome with bronchiectasis nor α1-antirypsin deficiency with bronchiectasis have 
been found to clearly predispose to pulmonary NTM (Kim et al. 2008, Sexton 
et al. 2008). Recently, rheumatoid arthritis was also linked to increased risk for 
pulmonary NTM infection (Al-Anazi et al. 2014). 
2.4 PATHOGENESIS 
The hydrophobic capsular lipid layer of mycobacteria is very protective against 
host defenses and supports mycobacteria evasion of phagocytosis and lysosomes 
(Fernando and Britton 2006, Astarie-Dequeker et al. 2010). Thus, mycobacteria 
are able to adapt and multiply in the intracellular environment of macrophages 
(Gupta et al. 2012, Maartens and Wilkinson 2007).
Rather few NTM species have a sufficient virulence to cause pulmonary NTM 
disease to immunocompetent patients with MAC as the best characterized group. 
MAC is a commonly used acronym for MAC which includes both M. avium and 
M. intracellulare. These two species are usually not reported separately by clinical 
microbiological laboratories, although M. intracellulare has been suggested to be 
more pathogenic than M. avium (Corbet et al. 1999, Han et al. 2005). Other species 
that have been definitely linked to pulmonary disease are M. kansasii, M. malmoense, 
M. xenopi, and some rapidly growing mycobacteria (RGM), including M. abscessus, 
M. fortuitum, and M. chelonae (Taiwo and Glassroth 2010). Of these, M. kansasii 
has been regarded to be the strongest pulmonary pathogen and M. abscessus 
causes the most cases of pulmonary RGM infection (Corbeta et al. 1999, Esteban 
et al. 2008). M. gordonae is usually considered a contaminant species, however, 
even in ATS 2007 criteria, M. gordonae has been reported to cause infections 
especially in patients with an underlying predisposition or immunosuppression 
such as AIDS, steroid therapy, or prostata and pulmonary carcinoma, in addition 
to patients undergoing peritoneal dialysis and transplant recipients (Eckburg et al. 
2000, Griffith et al. 2007, Pinho et al. 2009). M. marinum and M. ulcerans has not 
been reported to cause pulmonary NTM infections (Griffith et al. 2007), which is 
interesting, because M. marinum is closely related to M. tuberculosis. M. ulcerans 
is a well-known skin disease. The painless tropical, ulcerative cutaneous infection 
with extensive tissue damage in the absence of an acute inflammatory response is 
caused by mycolactone toxin (George et al. 2000).
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The infectious dose of NTM infection is largely unknown (Mirsaedia et al. 2014). 
The potential of different NTM species to cause a clinical infection is variable and 
the mechanisms are still not well understood (Fernando and Britton 2006). The 
development of NTM infection into symptoms and signs most probably depend not 
only on the infecting species but on local factors on the infection site and perhaps 
even more on the capability of host immune system to clear the infection before 
symptom onset. When aerosol droplets of NTM are inhaled by patients, most 
probably a disorder of innate local host defenses, mainly impaired mucociliary 
clearance, damaged respiratory mucosa or weakened cough response, will be behind 
a persisting infection and clinical symptoms in most cases (McGarvey and Bermudez 
2002). Many of these factors remain unknown, but the universal existence of NTM in 
the environment suggests that infection, i.e. contact with NTM alone, is not sufficient 
for clinical symptoms. Further, the pathogenesis of pulmonary NTM evidently 
differs from those of the disseminated gastrointestinal NTM infections (Guide and 
Holland 2002, Griffith et al. 2007). Patients’ ability to resist transmission of NTM 
depends on local and systemic host defense. The local pulmonary defects in the 
host might explain the oldest recognized risk factors for NTM infection, including: 
bronchiectasis, COPD, prior tuberculosis and persistent smoking (Mirsaedib et al. 
2014). These risk factors are associated with pulmonary tissue destruction, mucus 
plugging, and immunocompromise via disease or drugs, which partly explain the 
pulmonary pathogenesis (Mirsaedib et al. 2014). Mucus plugging and suppression 
of cough was suggested to be associated with pulmonary NTM infection and this 
phenomenon was labeled “Lady Windmere infection syndrome” (Reich and Johnson 
1992, Chalermskulrat et al. 2002). Among lung NTM patients, low nasal nitric oxide 
output and inhibition of ciliary movement as local defects have been observed in 
pulmonary NTM patients and have been suggested as the main or as some of the 
main underlying factors for infection (Fowler et al. 2013).
The underlying, hereditary pulmonary diseases, such as cystic fibrosis with 
reduced ciliary movement, alpha-1 antitrypsin (AAT) defect, and Marfanoid 
syndrome, predispose to pulmonary NTM, most probably through bronchiectasis 
and causing local barrier damage (Chan et al. 2007). In this process, fibronectin is 
thought to attach NTM on damaged mucosa (Middleton et al. 2000, Middleton et 
al. 2004). In contrast, the female, slender, nonsmokers with special morphotype 
have been suspected to have an immunological defect, which predisposes them to 
NTM infection (Guide and Holland 2002).
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2.4.1 GENETIC SUSCEPTIBILITY TO NTM
When mycobacteria have been phagocytized by macrophages, the intracellular 
infection of mycobacteria will activate the pro-inflammatory cytokine pathways and 
thus stimulate cytokine interleukin 12 (IL-12) and tumor necrosis factor- α (TNF-α) 
production (Haverkamp et al. 2006, Sexton et al. 2008). Interferon- γ (IFN- γ) 
stimulates innate and adaptive immunity, and coordinates major histocompatibility 
complex (MHC) class II expression on the surface of macrophages (Haverkamp et 
al. 2006). Moreover, it activates immunoglobulin (Ig) production by B-lymphocytes, 
contributing to the maturation of T-helper lymphocytes (Th) into the Th1 phenotype 
(Haverkamp et al. 2006, Field et al. 2006, Sexton et al. 2008, Guide and Holland 
2002). The complement system is stimulated by immunoglobulins and is involved 
in innate and acquired immune responses (Janeway et al. 2005). The complement 
system, an enzyme protein cascade, is regulated by complement genes, which are 
located in major histocompatibility complex (MHC) (Walport 2001, Fernando 
and Britton 2006, Senbagavalli et al. 2011). An activated complement opsonizes 
mycobacteria and may present mycobacteria to macrophages for engulfing (Walport 
2001). In the case of complement-protein malfunction, opsonization will be 
hampered and positive feedback of IL-12/IFN-γ on macrophages will be delayed 
(Gupta et al. 2012). INF-γ is essential in host defense against intracellular infection 
like mycobacteria and some salmonella species (Glosli et al. 2008). The possible 
malfunction of complement proteins are a result of defects of the complement 
genes due to mutations (Gupta et al. 2012), and malfunction may contribute to 
intracellular NTM survival.
Knowledge of human genetic susceptibility to mycobacteria is based primarily on 
pulmonary tuberculosis, which has been linked to major histocompatibility complex 
MHC class I, II, and III regions on chromosome 6 (Fernando and Britton 2006, 
Senbagavalli et al. 2011). Studies on pulmonary tuberculosis have suggested that 
susceptibility to tuberculosis is associated to some human leukocyte antigen (HLA) 
class I and II genes in several populations with variably and moderately increased 
risk for pulmonary tuberculosis (Yuliwulandari et al. 2010, Shi et al. 2011). Defects 
in MHC complement genes C2, C3, factor B (FB), and C4 have been studied in India 
and complete C4A deficiency, BF*FA and C3*F have been associated to pulmonary 
tuberculosis (Senbagavalli et al. 2011, Singh et al. 2007). Further, complement 
genes C2, C4 (C4A, C4B) and factor B (FB) are located in the MHC class III region 
between the class I (HLA-A, -C, -B) and the class II (HLADR,-DQ, -DP) (Fernando 
and Britton 2006, Senbagavalli et al. 2011). Defects in complement genes will 
produce quantitatively less active complement proteins, which will thus hamper 
the opsonization and positive feedback of IL-12/IFN- γ of the macrophages and 
mycobacteria will evade phagocytosis (Fernando and Britton 2006, Maartens and 
Wilkinson 2007). Rare data on genetic variation in the MHC region or on defects 
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in the complement cascade in NTM infections exists, but the data on tuberculosis 
make them interesting as study objects.
Disseminated NTM infection is clearly another entity than local pulmonary or 
cutaneous NTM infections. Some important observations have been made on NTM 
pathogenesis and host defense of disseminated NTM infection during the last three 
decades. Disseminated diseases have increased our knowledge on the principal 
components of the immune system for NTM defense. In immunocompromised 
HIV-patients, disseminated MAC infection has been thought to have its onset in 
entry of MAC through gastrointestinal mucosa to intestinal lymph nodes (McGarvey 
and Bermudez 2002). However, dissemination is usually seen only in HIV-patients 
with CD4+ T-lymphocyte number below 0.05 x 109/L, reflecting the important role 
of specific T-cell populations or activity (Orme and Ordway 2014).
While disseminated NTM infections are common among AIDS patients, 
pulmonary NTM infections are reported in less than 2.5% of AIDS patients 
(Kalayjian et al. 1995). Moreover, defects in T-cell mediated immunity have 
also been linked to disseminated NTM infections in solid organ or stem-cell 
transplantation patients (Doucette et al. 2004). However, neutropenia and humoral 
immune defects have not been linked to disseminated NTM infections (Kalayjian 
et al. 1995). Patients with immune modulatory agents such as TNF-α antagonist, 
biological medication, including monoclonal antibodies such as infliximab and 
adalimumab among rheumapatients, have been reported to be risk factors for 
disseminated NTM, in some cases (Salvana et al. 2007, Sexton et al. 2008). 
Disseminated NTM infections have been linked to rare familial genetic defects (Sexton 
and Harrison 2008, Guide and Holland 2002): a few mutations in IFN-γ and IL-12 
production in critical points leading to disseminated infections. The defects in IFN-γ 
and IL-12 production have been reported to be a critical pathway for host defense; 
MAC infections have been fatal (Foote 1999, Dorman and Holland 2000, Casanova 
and Abel 2002, Guide and Holland 2002, Haverkamp et al. 2006, Fernando and 
Britton 2006, Glosli et al. 2008). The genetic mutations are reducing cytokine signals 
of IL-12 or IFN-γ as consequence they are causing severe disseminated NTM and 
also BCG (bacillus Calmette-Guérin) or Salmonella infections (Guide and Holland 
2002). Mutations in IFN-γ receptor 1 and 2 have been identified in children and 
childhood with autosomal recessive patterns in 1994. These receptor deficiencies 
have caused severe disseminated MAC, RGM and Salmonella infections (Sexton 
and Harrison 2008, Guide and Holland 2002). However, these defects have not 
been found among pulmonary NTM patients (Fernando and Britton 2006, Holland 
2001). In addition neutralizing auto-antibodies against IFN-γ were observed in 
Asian adult patients with disseminated NTM infections. The patients with these 
antibodies had multiple opportunistic infections, which included disseminated 
RGM infections. The symptoms in this adult-onset immunodeficiency resembled 
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advanced HIV (Browne et al. 2012) To what extent the genetic defects IFN-γ and 
IL-12 pathways may be involved in local NTM infections has not been elucidated, 
but there are some studies on familial clustering of pulmonary NTM infections, 
suggesting a defect in the immune system (Colombo et al. 2010). 
The most common cutaneous NTM infections are caused worldwide by RGM, 
M. marinum, and and further in the tropics by M. ulcerans (Griffith et al. 2007). 
M.ulcerans and M. marinum affect host immune response differently. M. ulcerans 
is an extracellular bacterium and inhibits inflammatory response, whereas M. 
marinum is an intracellular pathogen and causes a strong inflammatory responses 
(Stamm and Brown 2004). M. ulcerans is causing tropical ulcerative skin disease 
(Boyd et al.2012). Painless tropical ulcerative cutaneous infection with extensive 
tissue damage in the absence of an acute inflammatory response is caused by 
mycolactone toxin (George et al. 2000, Stamm and Brown 2004). Mycolactone of 
M. ulcerans is able to induce a cytopathic effect and apoptosis including neutrophils 
and macrophages explains the absence of inflammation (George et al. 2000, Stamm 
and Brown 2004, Boyd et al.2012). M. marinum causes infection resulting in a 
subcutaneous granulomatous response (Stamm and Brown 2004). Pathologically 
cutaneous granulomas are like granulomas in lungs caused by M. tuberculosis 
(Stamm and Brown 2004). M. marinum skin infection may have a potential local 
spread and systemic dissemination in patients with rheumatoid arthritis or Crohn’s 
disease receiving TNF-α inhibitors (Ramos et al. 2010, Fallon et al. 2008).
Extrapulmonary NTM infections like lymphadenitis in children were primarily 
related to M. scrofulaceum in the 1970s.Thereafter, during the past 30 years, M. 
avium has been most often associated with children with lymphadenitis. The reason 
for this change is unknown (Falkinham 2002). 
2.5 CLINICAL MANIFESTATIONS 
Over 80% of NTM infections are pulmonary (Falkinham 1996, Griffith et al. 
2007, Piersimoni and Scarparo 2009), but cutaneous (Berliner 2015), soft tissue 
(Song et al. 2012, Hamade et al. 2014), lymph nodal (Penn et al. 2011), and bone 
infections (Wang et al. 2011, Park et al.2014) are also described. Rare infections 
in the central nervous system, cornea, and otitis media have also been reported 
(Griffith et al. 2007). Lymphadenitis caused by M. scrofulaceum is currently rare, 
because lymphadenitis is primarily caused by MAC, worldwide (Lindeboom et al. 
2005). In contrast, the most common reason for lymphadenitis in the UK and 
Scandinavia is M. malmoense. Rare skin, bone, and soft tissue infections may 
occur both in immunocompetent and immunocompromised patients as a result 
of occlusive injury, postoperative wound infections (Brickman et al. 2005, Dessy et 
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al. 2006, Kim et al. 2014, Cadena et al. 2014), contaminated tattooing (Kennedy et 
al. 2012), or nail manicuring (Winthrop et al. 2004). Disseminated NTM infections 
manifest as blood or bone marrow NTM-positive cultures and have been found 
mainly among HIV-patients with low CD4-count but also recently among severely 
immunosuppressed patients like solid-organ transplant patients (Doucette et al. 
2004, Al-Anazi et al. 2014). Disseminated NTM infections form an entity of their 
own and are not dealt with more in detail in this publication. However, very rare 
NTM bloodstream infections in immunocompetent patients have been associated 
with contaminated intravenous catheters in hospitals (Helou et al. 2013). 
2.5.1 PULMONARY NTM INFECTIONS
It has been estimated that more than 80% of pulmonary NTM infections are due to 
MAC; these are discussed separately in this chapter (Piersimoni and Scarparo 2009). 
In the 1950`s pulmonary NTM infections were reported in typical male smokers with 
alcohol abuse and an underlying lung disease. In radiological findings they had a 
cavitation in the upper lobes resembling M. tuberculosis.These first reported clinical 
cases of NTM pulmonary disease were caused largely by MAC and by M. kansasii 
and less often by M. malmoense or M. xenopi. Later reticulonodular appearances 
caused by MAC and M. kansasii were decripted by computer tomography (CT) 
(McGrath 2008). Radiological findings had a predilection for apical and posterior 
segments resulting in “tuberculosis–like disease” characterization (McGrath 2008). 
Furthermore, multiple lung lobes have been shown to be affected (Taiwo and 
Glassroth 2010). Cavitations had thick walls without air fluid level and in contrast 
to tuberculosis, pleural effusion was rare (Taiwo and Glassroth 2010). The symptoms 
were similar to TB with productive cough, haemoptysis, fever, sweats, and weight 
loss. The nodular MAC changes may be difficult to discern from adenocarcinoma, 
which is also common in this risk group of male ex-smokers (Kobashi et al. 2004). 
Symptoms were described similar to TB with productive cough, hemoptysis, fever, 
sweats, and weight loss. Table 2.5.1.
In 1989, Prince et al. described the second prototype of pulmonary MAC disease 
affecting mainly immunocompetent females (Prince et al. 1989). These patients with 
persistent cough were non-smokers or ex-smokers without underlying pulmonary 
diseases (Prince et al. 1989).
Radiological findings of bronchiolar inflammation in early disease process showed 
“tree-in-bud” pattern, which may progress slowly to fibronodular bronchiectasis 
without cavitation (Wickremasinghe et al. 2005). Radiological changes are most 
commonly observed in the right middle lobe and lingua associated with a productive 
cough. In 1992, Reich and Johnson created a theory on habitually suppressed cough 
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that would lead into collection of secretions and infection in the right middle lobe or 
lingual and they described this clinical picture as “Lady Windmere Syndrome” (Reich 
and Johnson 1992). These female patients were described to have a typical body/
morphotype: a lean body with bone deformities as scoliosis and pectus excavatum, 
and mitral prolapse (Guide and Holland 2002). These characteristic features also 
promoted the idea of a common immunological defect in these patients. Table 2.5.1.
The third pattern is rare, largely caused by MAC, and referred to as a 
hypersensivity syndrome which was first described after exposure to contaminated 
hot tubs (Mangione et al. 2001). Some vocational exposure to hot tubs that contain 
MAC caused hypersensitivity pneumonitis in lifeguards working at indoor swimming 
pools (Field et al. 2006) and aerosols that contain M. immunogenum in metal 
grinding workers have caused hypersensitivity pneumonitis (Field et al. 2006).
The symptoms of “hot tub lung” consist of subacute or acute dyspnea, fever and 
cough. NTM findings in sputum and inflammatory products support pathogenesis 
(Marchetti et al. 2004).The radiological findings are not typical, in CT or the high-
resolution computed tomography (HRCT) which may show alveolar or interstinal 
process with patchy or ground glass infiltrates, thickened interlobular septae, or 
interstitial nodules (Pham et al. 2003). Table 2.5.1.
RGM cause both pulmonary infections, but more often skin and soft tissue 
infections. Especially M. abscessus has been reported in 80% of RGM pulmonary 
diseases in the USA (Griffith et al. 1993). The classification of M. abscessus to 
subspecies M. abscessus, M. massiliense, and M. bolletii is clinically useful, 
especially in the case of treatment (Benwill and Wallace 2014). M. fortuitum and 
M. chelonae consist of remaining RGM pulmonary infections in the USA. In the 
M. abscessus pulmonary diseases, radiological findings demonstrate primarily 
nodular bronchiectasis, which rarely includes cavitation (Griffith et al. 1993). 
Gastroesophageal reflux has been reported to associate with RGM disease (Winthrop 
2010). Patients with cystic fibrosis are affected by M. abscessus in all ages, whereas 
MAC only presents in older patients (Wickremasinghe et al 2005). Table 2.5.1.
Radiological findings in M. malmoense pulmonary infections are reported as 
fibrocavitary changes associated with underlying pulmonary diseases such as COPD. 
Cavitary findings are typically a large cavity with a diameter of more than 6 cm 
and an air-fluid level is often present. Symtoms and signs resemble tuberculosis 
(Piersimoni and Scarparo 2008, Hoefsloot et al. 2009).
M. xenopi is usually found in elderly male smokers with underlying pulmonary 
diseases. Their radiological findings usually consist of fibrocavitary findings (Varadi 
and Marras 2009). Both respiratory symptoms (such as cough and haemotphysis) 
and systemic symtoms (like body-weight loss, low BMI, anemia, hypoalbuminemia, 
and elevation of inflammatory markers) are prominent manifestations (Hayashi 
et al. 2012). Table 2.5.1.
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M. kansasii is less often reported in Europe, in contrast to the USA 
where it is the second most common NTM isolation. M. kansasii is found 
in two subtypes while subtype 1 is common among immunocompetent and 
subtype 2 among immunocompromised patients (Maliwan 2005, Piersimoni 
and Scarparo 2008). Radiological findings are characterized as typically 
tuberculous fibrocavitary lesions in the upper lobes and on the other hand 
nodular bronchiectasis without cavities (Arend et al. 2004). Table 2.5.1. 
M. gordonae has been found in patients with underlying pulmonary (e.g. COPD) 
diseases (Henry et al 2004, Griffith et al. 2007).
Table 2.5.1. NTM pulmonary infections and classification according to clinical manifestation. Modifed 
according to Piersimoni and Scarparo 2008, Griffith et al.2007.
NTM pulmonary disease Grow-rate Clinical manifestation
Common
M. avium complex Slowly
Elderly male 60–80 years, heavy smokers, pre-
existing pulm disease :bilateral disease, usually 
cavitary or fibrocavitary 
Elderly female predominance 55–75 years, non-
smokers without pre-existing pulmonary diseases: 
nodular infiltrates with cylindrical bronchiectasis.
Male/ female predominance average age 36 
years:hot tub lung: diff use diseases: nodular 
infiltrates with cylindrical bronchiectasis due to MAC. 
M. kansasii,  
subtype I and II Slowly
Elderly men with upper lobe cavitations (subtype I).
Immunocompromised patients ( subtype II). 
M. malmoense Slowly Middle age or elderly men with fibrocavitary findings
M. xenopi Slowly Elderly men, heavy smokers, with upper lobe cavitations and nodules
M. abscessus Rapidly
Elderly female with multilobar interstitial and 
nodular lesions, rarely cavitations.
Uncommon
M. szulgai Slowly Elderly men with upper lobe cavitations and nodules
M. simiae complex,  
(M. simiae,  
M. lentiflavum,  
M. triplex)
Slowly Elderly men with upper lobe cavitations and nodules
M. celatum* Slowly
Elderly patients with upper lobe cavitations and 
nodules
M. chelonae Rapidly Infiltrates, nodules
M. fortuitum Rapidly Infiltrates, nodules
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2.5.2 EXTRAPULMONARY NTM INFECTIONS
Lymphadenitis occurs typically among children, most often aged 1–5 years (Griffith et 
al. 2007). In contrast, TB is a common cause of lymphadenitis in immunocompetent 
adults. In children, at day-care age, lymphadenitis due to M. tuberculosis consists of 
only 10–20% of all mycobacterial lymphanode infections (Falkinhamn 2003). NTM 
lymphadenitis in children is painless and unilateral involvement of submandibular, 
submaxillary, cervical, or preaurical lymphnodes (Wolinsky 1995). The disease has 
insidious course without systemic symptoms and the child is afebrile. Lymph nodes 
may be swollen for weeks or months, then they may finally rapidly soften and 
rupture, forming a draining sinus. MAC has been the main NTM in lymphadenitis 
of children followed by M. scrofulaceum, M. malmoense, and M. hemophilum 
(Lindeboom et al. 2005). In adults, NTM lymphadenitis is a rarity and most cases 
are due to M. tuberculosis. In AIDS patients, NTM lymphadenitis may be associated 
with a disseminated MAC infection (Falkinhamn 2003).
Most commonly skin and soft tissue NTM infections are caused by RGM like M. 
fortuitum, M. chelonae, and M. abscesssus and more rarely M. marinum and M. 
ulcerans (Esteban and Ortiz-Pe´rez 2009). The skin and soft tissue RGM infections 
may show a slightly different clinical picture depending on the causative species. Most 
often, M. fortuitum, appears in immunocompetent persons after penetrating trauma 
or surgery (Piersimoni and Scarparo 2009). Clinical cutaneous findings are nodular 
or ulcerating with slight exudate and reddish blue discolorations. M. chelonae and 
M. abscessus clinical manifestations appear as multiple and disseminated lesions as 
a result of bacteremic spread, and they are often associated with immunosuppressive 
underlying disease, transplant organ, or steroid-treatment (Piersimoni and Scarparo 
2009). However, the spectrum of diseases due to M. chelonae and M. abscessus is 
wide and cutaneous infections like folliculitis and postsurgical infections like after 
mammoplasty or even in wounds after soil contamination, may be seen as was 
described in many casualities of the Thailand tsunami 10 years ago (Groote and Huitt 
2006). Outbreaks related to contaminated equipment or dye have been reported 
related to skin punctures as tattoo or manicure saloons (Groote and Huitt 2006). 
Symptoms and signs might appear in cutaneous infections as early as 3 weeks but 
may delay up to 4 months (Piersimoni and Scarparo 2009). Cutaneous infection 
caused by MAC after cutanous injection, trauma, or surgery reveals skin ulceration 
and abscesses. Further, MAC skin infection with indolent erythematous dermatitis 
may mimic Lupus vulgaris (Piersimoni and Scarparo 2009).
M. marinum infections have been associated to fish tanks, home aquaria, and 
swimming pools. Infection may also be obtained from skin-penetrating traumas 
from fish fins or bites (Piersimoni 2012). In M. marinum skin infections, 50%–80% 
of patients have had an aquarium at home or at a work place, or a swimming pool 
contact or fish contact at work (Piersimoni 2012). A cutaneous disease in peripheral 
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extremities may cause “fish tank granuloma” or “swimming pool granuloma” and 
may migrate to other areas, especially joints or bones (Escalonilla et al. 1998, Aubry 
et al. 2002). 
After inoculation, small nodules begin to grow in 2–3 weeks making skin 
abscesses. M. marinum infection may spread proximally along the lymphatics 
producing additional “sporotrichoid spread” nodules. Sometimes, rarely, it may 
cause disseminated infections (Streit et al. 2006). M. marinum skin infection has 
been reported in rare cases to spread locally or experience systemic dissemination 
in patients with rheumatoid arthritis or Crohn’s disease receiving TNF-α inhibitors 
(Ramos et al. 2010, Fallon et al. 2008).
M. ulcerans inoculates the skin through a cut or wound contaminated with 
water, soil, or vegetation (Esteban and Ortiz-Pe´rez 2009). Clinically cutaneous 
nodules and ulcers affect 62% in a lower limb and 30% in an upper limb (Asiedu 
et al. 2000). The incubation time is generally under 3 months. Affected patients are 
often children under 15 years-of-age (Piersimoni and Scarparo 2009). Spontaneous 
healing usually takes 4–6 months and involves extensive scar formation, resulting in 
severe deformity with joint contracture, subluxation, muscle atrophy, or distal lymph 
edema (Asiedu et al. 2000). Multiple lesions represent the most severe form of the 
disease; a high percentage of cases are osteomyelitis, often leading to amputation 
or even death. Disabilities are frequent after M. ulcerans infection and have been 
estimated in 25% to 58% of cases (Piersimoni et Scarparo 2009, Asiedu et al. 2000).
Biopsies of NTM skin infections have demonstrated suppurative granuloma and 
abscesses with necrosis, but without caseation and acid fast stains may be positive 
(Piersimoni and Scarparo 2009). Symptoms and signs may appear in cutaneous 
infections as early as 3 weeks but may delay up to 4 months (Piersimoni and Scarparo 
2009). NTM infection may involve the visceral organs and M. avium, subspecies 
paratuberculosis has been described in some human cases to relate intestinal Crohn’s 
disease (Falkinham 1996).
2.5.3 DISSEMINATED NTM INFECTION IN IMMUNOCOMPROMISED PATIENTS 
Disseminated NTM diseases are seen in patients with impaired cellular immunity, 
HIV patients with low CD4 + T-cell counts, transplant recipients, hematological 
leukemia patients, patients with autoimmune disease treated with a biological drug 
or chronic corticosteroid medication, and a few genetic disorders of interferon 
gamma production and function (Griffith et al. 2007, Piersimoni 2012, Doucette 
and Fishman 2004, Dorman and Holland 2000, Casanova 2002).
Over 90% of HIV disseminated cases are caused by MAC, largely due to 
M. avium (Griffith et al. 2007). Infection with NTM is a rare event in forms of 
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immunosuppression other than advanced HIV, but infections have been reported 
after organ transplantation, in connection to hematological malignancies, and 
also in patients receiving to chronic corticosteroid medication or TNFα-antagonist 
(Doucette 2004, Cordonnier 2004, Griffith et al. 2007).
Patients undergoing solid-organ or stem-cell transplantation are at moderate 
risk for NTM infection, especially during the second through sixth post-transplant 
months as a result of cumulative immunosuppression. NTM infections due to 20 
different species (both slowly growing NTM and RGM and also species with low 
virulence such as M. genavense and M. haemophilum) have been reported after 
transplantation (Piersimoni 2012, McGarth et al. 2008). 
Infection risk seems to correlate with immunosuppression needed after 
transplantation and an incidence of 0.16–0.38% after renal transplantation, 0.24–
2.8% after heart, and 0.46–2.3% after lung transplantation have been reported 
(Piersimoni 2012).
The most common forms of NTM infection after organ transplantation are 
cutaneous lesions of the extremities, tenosynovitis, arthritis with a causative agent, 
M. fortuitum, M. abscessus, and M. chelonae, moreover half of these NTM infections 
are associated to disseminated infection (Piersimoni 2012). The clinical picture of 
the skin infections are painful, erythematous or violaceous nodules progressing 
to abscess draining fluid. Sometimes they might enlarge to necrotic cellulitis and 
require surgical treatment. Notably, the systemic symptoms like fever, weight 
loss, night sweats, and leukocytosis are absent. Among lung and heart transplant 
recipients, pleuropulmonary NTM diseases appear in 26 %–82 % of reported 
cases and they are often caused by M. kansasii, M. avium, M. abscessus, and M. 
xenopi (Piersimoni 2012). Among lung transplant patients, pulmonary MAC and 
M. abscessus infections are the most common with symptoms involving persistent 
cough, dyspnea, and sputum production (McGarth et al. 2008). It is worth observing 
that over half of these pulmonary cases also include skin, joint or soft tissue infections 
(Piersimoni 2012). In contrast, in kidney transplantations pulmonary NTM lung 
infection has rarely been reported, instead in renal transplantation NTM infections 
at postsurgical sites cause the majority of dissemination due to M. chelonae and M. 
abscessus (McGarth et al. 2008). Both types of infection occur in later years after 
transplantation and a median time of onset of 48 months after transplantation has 
been reported. For kidney, time onset has been described to be 24 mo, for lung 15 mo, 
and for heart 30 mo (Piersimoni 2012). Life-time immunosuppression after organ 
transplantation seems to increase the cumulative risk for NTM infection (Doucette 
and Fishman 2004). Consequently, decreased immunosuppressive medication may 
protect patients against NTM infections.
Patients with rheumatoid arthritis receiving TNF-α-antagonists (infliximab, 
toshilitsumab) have been reported to possess an increased risk of tuberculosis 
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reactivation and the treatment can thus be thought to render them more sensitive 
to NTM infections. TNFα-antagonist impairs granuloma formation. In addition, 
nitric oxidase synthase decreases affecting macrophage defense mechanisms 
(Raychaudhuri et al. 2009).
2.5.4 HEALTH CARE RELATED NTM INFECTIONS 
RGM, especially M. fortuitum and M. abscessus have been reported in health-
care-associated outbreaks. The reason for outbreaks is primarily that patients are 
exposed to NTM infected liquid, e.g. tap water given the resistance of mycobacteria 
to chlorine, formaldehyde, alkaline glutaraldehyde, and other commonly used 
disinfectants (Groote and Huitt 2006, Helou et al. 2013). Contaminated tap water, 
used for rinsing surgical devices after disinfection, was identified as the source of 
the outbreak in 1993 when 58 cases of M xenopi spinal infection were identified 
after microsurgery operation (Astagneau 2001). Catheter-related RGM bloodstream 
infections were identified altogether in 116 patients with hematologic or solid cancer. 
A treatment response was moderate in 92 patients (96%), but three patients had 
complications: one complication with endocarditis in a mitral valve caused by M. 
chelonae and two patients had complications with thrombophlebitis (Helou et 
al. 2012). NTM outbreaks have been associated with cardiac surgery (primarily 
median sternotomy wounds and cardioplegia solution), injections, plastic surgery, 
liposuction, dialysis-related outbreaks, and central intravenous catheters (Philips 
and von Reyn 2001, Griffith et al. 2007). Recently, M. chimaera caused a prolonged 
outbreak to 6 adult patients that had valve endocarditis or vascular graft infection 1.5- 
3.6. years after postoperative open-chest heart surgery in Europe. Epidemilogical and 
microbiological findings linked heater-cooler water tanks used in cardiac surgery, 
which was contaminated with M. chimaera which transferred to patients during 
open–heart surgery. All 6 patients were treated with prolonged antimycobacterial 
therapy. Three of the patients were reoperated for valve replacement surgery, two 
others died (Sax et al. 2015).
In hospitals RGM bloodstream infections in humans are caused by about 20 
species of RGM, largely through catheter-related infections. RGM are capable of 
creating biofilm and colonizing intravascular catheters. Catheter-related bloodstream 
infection symptoms are systemic; fever, chills, and local infection. RGM infections 
in cardiac implantable devicies or prosthetic valves are usually subacute, but the 
mortality rate may be up to 25% (Helou et al. 2013).
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2.6 DIAGNOSIS OF NTM INFECTION
2.6.1 LABORATORY DIAGNOSIS OF NTM
NTM and Mycobacterium tuberculosis appear to be similar under the microscope. 
In the laboratory, however, the growth rates and colony pigmentation of NTM 
provide practical means for grouping. Modern culture techniques and molecular 
techniques provide more rapid molecular diagnostic systems. As such, NTM have 
been classified into three groups: slowly, intermediately, and rapidly growing. 
Rapidly-growing NTM reach maturation within 7 days and are classified in the 
laboratory according to pigmentation and genetic relatedness. Intermediately 
growing mycobacteria need 7 to 10 days to mature. Some slowly growing NTM 
may require nutrional supplementation, because they are growing more than 7 
days with one exception. The cultivation of M. ulcerans requires up to several 
months to grow and identification by molecular detection is most useful. 
In the laboratory, clinical microbiological samples, except blood, are first stained 
with flourochrome dye (Woods 2002). To prevent overgrowth of Pseudomonas 
aeruginosa and other bacteria, the specimens are treated with sodium hydroxide 
and N-acetylcysteine. Thereafter the samples are cultured in both solid and liquid 
media. On solid media the growing takes 3–6 weeks for slowly growing NTM, but 
is shortened to 1–2 weeks in liquid media. The most modern techniques are used 
to differentiate mycobacteria specimens: high-performance liquid chromatography, 
restriction fragment length polymorphism analysis amplification techniques, DNA 
sequencing, and the use of DNA probes (Petrini 2006).
Cultures positive for acid-fast bacilli are identified by conventional biochemical 
tests; MTB is differentiated from NTM through its catalase, nitrate reductase, and 
niacin production. Nucleic acid amplification techniques, hybridization with DNA 
probes (AccuProbe; Gen-Probe, San Diego, CA, USA), distinguish NTM from MTB. 
In case cultures negative for M. tuberculosis and MAC complex, NTM are identified 
by amplification and sequencing of the 16S rRNA gene (Petrini 2006).
2.6.2 DIAGNOSTIC ATS CRITERIA
Emanuel Wolinsky suggested the use of acid fast bacilli (AFB) sputum cultures in 
NTM lung diagnosis and thereby recognized NTM cases grew. In 1979, Wolinsky 
published the first review of NTM diseases, including diagnosing NTM lung 
disease, describing “chronic pulmonary disease resembling tuberculosis” and noted 
M. kansasii and MAC to be the most common pulmonary pathogens (Wolinsky 
1979). To distinguish pulmonary NTM from pulmonary tuberculosis, more frequent 
positive NTM culture findings were necessary and the microbiolgical findings 
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constituted the cornerstone of diagnosis. These concepts suggest the repetitive 
isolation of an NTM species in culture with radiological cavitation findings mimicking 
M. tuberculosis. In 1981, the American Thoracic Society (ATS) published the first 
diagnostic guidelines for M. kansasii and M.avium complex, including radiological 
findings with cavitations or infiltrates, and isolations of mycobacteria from biopsy 
tissue together with histopatological changes. Later, noncavitary MAC lung disease 
was revealed and the modification of the diagnostic criteria for MAC and M. kansasii 
was suggested, including specific radiological and microbiological criteria. This was 
included in the publications in 1990 by ATS: In the presence of a noncavitary 
infiltrate, NTM lung disease is considered to be present when at least two sputums 
are AFB smear-positive and/or moderate to heavy growth on culture (Wallace et 
al. 1990). The typical patient with infection caused by MAC was a heavy smoking, 
immunocompetent elderly white man with a chronic lung disease. The signs and 
symptoms in NTM lung disease were similar: cough, shortness of breath, fatigue, 
fever, weight loss, and decreased appetite (Piersimoni and Scarparo 2008; Kubo 
et al. 1998). Soon after these opportunistic bacteria revealed to be an important 
illness in patients with severe, immunocompromised underlying disease, AIDS, 
among HIV-patients (Benson 1994). Later on NTM were found more frequently 
in other immunocompromised patients, such as hematologic and cancer patients 
(Doucette and Fishman 2004, Cordonnier et al. 2004). 
Moreover in the late 1980s, NTM diseases in patients without underlying diseases 
came up in non-smoking, eldery white women with noncavitary MAC diseases. 
Prince et al described 21 patients with MAC lung disease: eldery women without 
known predisposing factors or lung disease (Prince et al. 1989). Most of them had 
slowly progressive nodular opacities, 29% had some cavitary abnormalities, and 
some developed cavitary during the course of disease. The important aspect was 
the understanding of noncavitary MAC disease, namely progressive; nodularic MAC 
lung disease could even be fatal. The modern radiological CT-scanning revealed 
obvious noncavitary MAC lung disease, small nodules, and fibrosis. A Japanese study 
confirmed these findings and emphasized CT as a diagnostic tool (Tanaka et al. 1997). 
CT-scanning was included into the ATS criteria in 1997. The radiographic criteria 
included the lung findings: infiltrate, nodular, or cavitary disease found by x-ray or 
multifocal bronchiectasis and/or multiple small nodules found by HRCT (Wallace 
et al. 1997). Microbiological criteria fit best with M. avium complex, M. abscessus, 
and M. kansasii. Three positive NTM cultures with negative AFB smear results 
from sputum/bronchial wash during the last 12 mo or appropriately two positive 
cultures and one positive smear finding. When those findings were nondiagnostic 
or another disease was unable to exclude positive NTM findings, transbronchial or 
lung biopsy fulfilled the criteria. Alternatively, biopsy findings with granulomatous 
inflammation and/or AFB and one or more sputum or bronchial washings are 
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positive for an NTM even in low numbers. When only one bronschial wash was 
available, one positive culture with a 2+,3+,4+ AFB smear or 2+,3+,4+ growth on 
solid media fulfilled microbiological criteria (Wallace et al. 1997). 
Colonization of pulmonary NTM in immunocompetent and immunocompromised 
patients has been discussed, because there has been discrepancy between sputum 
findings and symptoms (Field and Cowie 2006). NTM might be found in patients 
with clinical symptoms without causal relation to symptoms. Airway colonization 
might be difficult to separate from a clinical disease. Treatment of colonization might 
lead to unnecessary adverse effects. As a result, the existence of a low-grade NTM 
infection is unclear. It has been proposed that “colonization” be replaced with the 
term “indolent disease” (Piersimoni and Scarparo 2008, Field and Cowie 2006).
This aspect has been taken into consideration in the ATS criteria 2007: at least 
two positive NTM sputum cultures or histopathological findings are required. 
Moreover radiographic findings and pulmonary symptoms fit for NTM disease 
are required. See Table 2.6.2 (Griffith et al. 2007). The challenge in diagnosing 
NTM lung disease is the variability in clinical symptoms and findings depending 
on the causative species, underlying diseases, and difference in immunocompetent 
and immunocompromised patients. Cough is a common symptom, but other 
symptoms like malaise, fatigue, sputum production, dyspnoea, weight loss, fever, 
or haemoptysis are seen variably (Griffith et al. 2007). Radiologically and clinically, 
NTM resembles pulmonary tuberculosis and pulmonary cavities resembling those 
seen in tuberculosis have been described to be associated to M. kansasii in heavy-
smoking men (Ellis et al. 2002). The cavitations are a less frequent manifestation 
of disease due to MAC, where bronchiectasis with nodules has been frequently 
reported (Piersimoni and Scarparo 2008, Griffith et al. 2007, Kubo et al. 1998). 
However, disease forms with nodular or fibrotic changes are also common and 
none of the radiological findings can be considered pathognomonic for an NTM 
infection (Griffith et al. 2007). If ATS criteria 2007 are not fulfilled, the follow-up 
of suspected NTM patients is emphasized because the nature of NTM is slowly 
progressive (Griffith et al. 2007). However, ATS 2007 criteria have been evaluated 
only in a few modified criteria studies, if the criteria have the prognostic value or 
the response to NTM treatment (Andréjak et al. 2010, Hayashi et al. 2012).
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Table 2.6.2. ATS guidelines 2007 on the diagnosis of NTM disease. 
- 52 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
at least two separate 
sputum positive samples 
at least one positive 
bronchial wash or lavage 
transbronchial or lung 
biopsy with 
granulomatous 
inflammation or  AFB 
and positive culture for 
NTM 
biopsy with 
histopatological 
features of NTM with 
one or more sputum or 
bronchial washings 
culture positive 
Microbiological criteria 
One of the following microbiological 4 
criteria required
Radiological criteria Symptom criteria 
nodular or cavities 
on x-ray 
respiratory symptoms: 
cough, dyspnoea 
multifocal bronchiectasis with 
multiple nodules on CT /HRCT 
systemic symptoms : 
fever, weight loss, 
fatigue 
or  
or 
or 
or +/- 
positive diagnosis of NTM disease 
exclusion of other 
dg: TB, malignacy 
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2.7 TREATMENT OF NTM INFECTIONS
2.7.1 TREATMENT OF NTM AMONG IMMUNOCOMPETENT PATIENTS
Even though NTM and tuberculosis are both mycobacteria infections, their treatment 
is different. The therapy of tuberculosis has defined protocols, susceptibility testing, 
and a less complicated regimen (McGrath et al. 2008). To optimize the clinical 
cure for pulmonary NTM patients, the clinican must first estimate whether NTM 
culture findings represent true pathogenesis or colonization. Further benefits of 
the treatment versus side effects to the patients must be evaluated (Piersimoni 
and Scarparo 2008, Esteban et al. 2009, Al-Anazi et al. 2014). The aim of the 
drug treatment might be definitive eradication or be suppressive minimizing of 
the symptoms. The drug combinations with surgery have to take priority in cases 
where the NTM disease is pulmonary unilateral or locally cutaneous (Esteban et al. 
2009). It is unclear if patients need different regimens, when clinical manifestations, 
risk factors and patient’s characteristics are different, as in the case of cavitary and 
nodular bronchiectatic pulmonary NTM diseases (Ingen et al. 2013). 
It is important to consider the differences between pulmonary and disseminate 
NTM pathogenesis when treating NTM cases. Namely, pulmonary NTM infection 
due to MAC and other slow growing NTM tends to occur in immunocompetent 
patients both with and without underlying lung disease; e.g. bronchiectasis, 
COPD, prior tuberculosis, and cancer. The treatment of co-morbidities have to be 
considered when evaluating the period of NTM therapy, patients compliance, and 
surgery requirement (Esteban et al. 2009). However, even with modern laboratory 
diagnoses and new antimicrobial drugs, treatment outcomes of NTM are typically 
poor (Piersimoni and Scarparo 2008) and unfortunately treatments according 
guidelines do not necessary improve the prognosis of immunocompetent NTM 
patients (Andréjak et al. 2013). A valid combination of several drugs should give a 
synergistic effect and avoid drug resistance. Moreover if surgery has to be considered, 
good collaboration between microbiologists, clinicians and surgeons is important 
(Esteban et al. 2009, Griffith et al. 2007, Al-Anazi et al. 2014).
The treatment of slowly growing NTM (MAC, M. malmoense, M. xenopi) 
includes the first-line antituberculous drugs rifampin and ethambutol combined 
to clarithromycin or to an aminoglycoside. Resistance to isoniazid is common and 
is not advised (Brown-Elliot et al. 2012). Macrolides have been the most important 
advancement in the treatment of MAC pulmonary disease (Wallace et al.1996, 
Tanaka et al. 1999, Griffith et al. 2007). In contrast, RGM are intrinsically resistant 
to first-line antituberculosis drugs. Therefore the treatment combinations consist of 
a macrolide and/or a quinolone with amikacin. Further, other antibiotics (cefoxitin, 
doxycycline, cotrimoxazole) may be valid (Griffith et al. 2007). 
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According to ATS 2007 guidelines, macrolides form the cornerstone of 
antimycobacterial treatment of MAC. The treatment of M avium complex pulmonary 
disease is advised to be treated with a combination of a macrolide (clarithromycin or 
azithromycin), ethambutol, and rifampicin avoiding macrolide monotherapy, which 
leads to rapid resistance and treatment failure (Griffith et al. 2007, Piersimoni and 
Scarparo 2008, Brown-Elliot et al. 2012). An intermittent thrice-weekly regimen is 
recommened only for patients with limited disease or nodular bronchiectatic disease 
(Taiwo and Glassroth 2010). Treatment should be continued until sputum cultures 
have been negative for at least 12 months. During treatment, sputum samples are 
advised to be collected monthly (Griffith et al. 2007). Daily therapy is recommended 
to MAC patients with cavitary disease or extensive bronchiectatic MAC, or patients 
with previous treatment failure and further in that case, a parenteral aminoglycoside 
are combined like streptomycin or amikacin for the first 8 to 12 weeks (Griffith et 
al. 2007, Piersimoni and Scarparo 2008, Taiwo and Glassroth 2010). Surgery is 
recommended in pulmonary MAC, in case there is a localised fibrocavitary disease 
or macrolide resistance (Griffith et al. 2007, Piersimoni and Scarparo 2008, Taiwo 
and Glassroth 2010). 
M. xenopi treatment according to ATS 2007 guidelines are including 
clarithromycin, rifampin, isoniazid, and ethambutol (Griffith et al. 2007). The 
regimen is recommended for 18–24 months. Out of quinolones, moxifloxacin may 
be effective, but experience is limited (Taiwo and Glassroth 2010, Brown-Elliot et 
al. 2012). M. malmoense treatment with rifampicin, ethambutol with or without 
macrolide or quinolone should be up to 24 months (Griffith et al. 2007). The growth 
of M. malmoense may be poor and therefore in vitro susceptibility is difficult (Brown-
Elliot et al. 2012). Symptoms relapse and progressive lung destruction determined 
radiographically are signs to overweight resectional surgery, provided that extensive 
lung involvement is excluded (Taiwo and Glassroth 2010). 
RGM pulmonary infections are caused mainly (80%) by M. abscessus. M. 
abscessus subsp. massiliense is macrolide susceptible and treatment is successful. 
Instead the treatment challenge is M. abscessus subsp. abscessus, because 80% of 
isolates are macrolide resistant due to the erm- gene (Benwill and Wallace 2014). 
The treatment is difficult and rarely curable in patients with underlying pulmonary 
diseases (Taiwo and Glassroth 2010). Immunocompetent patients require up to 24 
months multidrug treatment with macrolide, amikacin, cefoxitin or imipenem, and 
even so relapses are usual (Jeon et al. 2009, Taiwo and Glassroth 2010, Brown-
Elliot et al. 2012, Beltrame et al. 2013). Co-infection with MAC has been reported 
in 15% of cases (Taiwo and Glassroth 2010). Surgical resection is necessary in 
claritromycin resitant MAC and M. abscessus pulmonary infections (Griffith et al. 
2007, Taiwo and Glassroth 2010, Brown-Elliot et al. 2012, Kang et al. 2015). In a 
retrospective observational study over 2001–2008, 107 non-smoking women with 
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bronchiectasis carried a pulmonary M. abscessus infection and half of the patients 
had MAC co-infection. The patients were treated with antimycobacterial drug, 
with or without surgical intervention, and patients were followed for 34 months. 
The treatment outcome was poor but similar in both groups. As a result, 29% of 
patients remained culture positive, 23% had relapses, and mortality rate was 16%. 
Surgical resection showed some success; sputum cultures converted to negative in 
48% of patients (Jarand et al. 2011). In another retrospective review, a total of 70 
adult patients with pulmonary NTM underwent pulmonary operation due to poor 
response to drug therapy, cavitary lesions, or severe bronchiectasis or hemoptysis. 
A negative sputum culture was achieved and maintained in 57 (81%) patients. A 
complication rate of 21% was rather high due to usual complication bronchopleural 
fistula and moreover one patient died (Kang et al. 2015). Today, indications for 
surgery are unclear and careful patient selection is important (Mirsaeidia et al. 2014). 
The adjunctive treatment of patients with inhaled interferon- γ in functional IFN-γ 
deficiency with pulmonary NTM disease has been found controversial (Hallstrand 
et al. 2004, Lam et al. 2006) and treatment of inhaled amikacin has been reported 
without any outcome benefit (Ingen et al. 2013). 
Localized cutaneous infections are associated often to skin, soft tissues, lymph 
nodes, tenosynovitis, and bones. Ocular or otitis, or even central nervous system 
diseases, are rarely reported (Piersimoni and Scarparo 2009). Cutaneous MAC 
infection requires frequent surgical depridement with 6–12 months therapy with 
at least 3 drugs, usually clarithromycin, rifampin, and ethambutol (Piersimoni and 
Scarparo 2009). RGM cutaneous infections are needed to treat 4–6 months. M. 
fortuitum infection in surgical sites or after penetrating skin trauma treatment may 
include amikacin, cefoxitin, fluoroquinolones, sulfonamides, and imipenem. M. 
abscessus and M. chelonae are susceptible to clarithromycin, amikacin, imipenem, 
and also linezolid (Brown-Elliot et al. 2012). Surgery is useful to assess severe 
cutaneous infections. M. fortuitum cellulitis, M. abscessus, or M. chelonae abscesses 
or osteomyelitis (Piersimoni and Scarparo 2009, Brown-Elliot et al. 2012). In M. 
marinum infections, two antimicrobial claritromycin with rifampin or ethambutol 
3–6 months is usually sufficient (Piersimoni and Scarparo 2009, Brown-Elliot et 
al. 2012). At least three drugs are needed in deeper soft tissue and tenosynovitis 
infections: macrolide with rifampin, ethambutol, and fluoroquinolones with or 
without amikacin or linezolide for 12–18 months. Moreover, surgical debridement 
is necessary for deep abscesses (Aubry et al. 2002).
In lymphadenitis of NTM, excision seems to be the treatment of choice 
(Piersimoni and Scarparo 2009). In a retrospective study of 1986 to 1998, of 57 
children with NTM lymphadenitis over a 12-year period, it was revealed that excision 
gave a higher rate of healing and re-operations were needed less often (Flint et al. 
2000). In another study of 100 children with NTM lymphadenitis, surgery was 
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more effective than antimycobacterial medications with a cure rate of 96% vs 66% 
(Lindeboom et al. 2007). 
2.8 PROGNOSIS OF NTM INFECTION
2.8.1 PROGNOSIS OF PULMONARY NTM INFECTION
In general, NTM infection carries a poor prognosis. In a Danish population-based 
study, 40% of the patients with a definitive NTM disease had died within 5 years 
of NTM isolation (Andréjak et al. 2010). The prognosis was no different in patients 
who were regarded to have NTM colonization only. Overall 5-year mortality of ATS-
criteria-positive MAC-pulmonary-infection patients was 24%, and 10-year mortality 
47 % (Hyashi et al. 2012). In the latter study, MAC-infection related mortality was 
estimated to be only 5.4% within 5 years and 15.7% within 10 years, respectively. 
In contrast, M. kansasii pulmonary infection was reported to cause death only in 
8% of patients (Maliwan et al. 2005). Five-year mortality in M. xenopi pulmonary 
disease was 15% in a review of cases during 1960–2008 (Varadi and Marras 2009). 
Five-year mortality in M. malmoense pulmonary infections has been reported to 
be 11–13% (Hoefsloot et al. 2009, Henry et al. 2008). Patient age and underlying 
comorbidities in M. xenopi pulmonary NTM associated up to 69% with mortality 
in 3-year surveillance in France (Andréjak et al. 2009). In a recent study of all 
adults in Denmark with at least one NTM-positive pulmonary specimen during 
1997–2008, M. xenopi and M. malmoense had the worst prognosis with up to 51% 
mortality rate in 5-year surveillance. The impact of NTM disease on mortality seems 
to be increasing as suggested by death-certificate data from the USA. A significant 
increase in the annual number of NTM-related deaths was observed in 1999–2010 
(Mirsaeidib et al. 2014). However, when adjusted for age, no increase during this 
period in fatal cases related to NTM isolation was seen. These studies fail to point 
out the immediate impact of NTM infection on mortality but merely show that 
NTM isolation is a sign of poor prognosis. In ATS criteria, positive MAC pulmonary 
disease, MAC-specific mortality, was estimated to be only 5% (Hayashi et al. 2012). 
2.8.2 PROGNOSTIC FACTORS IN PULMONARY NTM INFECTION
Infections due to different NTM species seem to have a variable prognosis (Gommans 
et al. 2015). M. xenopi and M. malmoense had higher 5 year and 10 year mortality 
rates than MAC in a Danish study, but other non-rapidly growing mycobacteria 
and RGM had a better prognosis than MAC (Andréjak et al. 2010, Gommans et al. 
2015). Cutaneous NTM infections may spread locally but fatal outcome is a rare 
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exception. No death was observed from 63 M. marinum cases, although treatment 
failure was observed in 13% of patients (Aubry et al. 2002).
ATS criteria were developed to find patients who would be in need of 
antimycobacterial medication, however no difference in prognosis was seen 
between patients who did and did not fulfil the modified ATS criteria (Andréjak et 
al. 2010). There seems to be somewhat contrasting results on the effect of gender 
on outcome. In a Danish study on all NTM infections, women were observed to 
have significantly better prognosis than men but in a similar analysis from the USA, 
no gender bias regarding mortality was seen (Andréjak et al. 2010, Mirsaeidib et al. 
2014). Male gender was, however, a prognostic factor predicting poor outcome in 
MAC pulmonary disease (Hyashi et al. 2012). Older age has also invariably been 
a prognostic marker for poor outcome (Andréjak et al. 2010, Hyashi et al. 2012, 
Commans et al. 2015). The extent and type of pulmonary infection, as well as 
underlying pulmonary disease, have been related to poor prognosis. Smear-positive 
cases, where the NTM load is probably higher than in smear negative cases, had 
a poorer 5-year survival (Andréjak et al. 2010). Fibrocavitary MAC disease was 
observed to have poorer prognosis than nodular-brochiectatic disease (Hyashi et 
al. 2012). However, underlying pulmonary diseases like fibrocavitary bronchiectasis 
have been associated to poor prognosis (Kim et al. 2008, Hyashi et al. 2012). 
In addition, COPD, bronchiectasis, interstitial lung diseases, and smoking were 
frequently found in deceased cases with NTM (Mirsaeidib et al. 2014). Various 
underlying diseases are common and they have generally been strongly associated 
as risk factos for fatal outcome. It is known that pre-exiting pulmonary diseases 
are risk factors and predispose to NTM disease, e.g. bronchiectasis, COPD, prior 
tuberculosis, and frank immunosuppressive states (Piersimoni and Scarparo 2008, 
Fowler et al. 2006, Wickremasinghe et al. 2005). Furthermore, studies indicate that 
particular NTM species, risk factors such as underlying comorbidities, advanced age, 
and male sex had a prognostic factor among immunocompetent patients (Taiwo and 
Glassroth 2010, Hoefsloot et al. 2009). Low BMI has also been a poor prognostic 
factor (Hyashi et al. 2012).
2.8.3 PROGNOSIS OF DISSEMINATED NTM INFECTION
Patients with disseminated NTM infections with underlying immunosuppressive 
diseases, congenital deficiencies, or genetic mutations are known to have 
a poor outcome (Al-Anazi et al. 2014, Holland et al. 2002). In contrast, 
immunosuppressive patients with lower immunosuppressive level, receiving 
treatment regimen, and catheter removal experience a better prognosis (Al-Anazi 
et al. 2014, Helou et al. 2013).
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3 AIMS OF THE STUDY
The purpose of the present study was to investigate the clinical symptoms and 
underlying diseases in non-HIV patients with an isolation of NTM. 
The specific aims were:
I To study the role of smoking as a risk and prognostic factors among patients 
with NTM infection by comparing underlying diseases, clinical symptoms, and 
survival.  
II To compare clinical picture, symptoms, and survival according to fulfilment 
of The American Thoracic Society 2007 (ATS) diagnostic criteria and evaluate 
the prognostic value of the ATS criteria in HIV-negative NTM patients.
III To evaluate differences in underlying diseases, symptoms and signs, radiological 
findings, survival, and prognostic factors among patients with MAC and patients 
with other NTM categorized according to the 2007 American Thoracic Society 
(ATS) NTM case definition.
IV To assess the genetic deficiency of complement components C4A or C4B encoded 
by major histocompatibility complex as a plausible risk factor in patients with 
pulmonary NTM infections and in M. tuberculosis patients. 
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4 MATERIALS AND METHODS
4.1 PATIENTS (STUDY I–IV) 
Studies I–II were based on retrospective laboratory-based surveillance data on 
adult patients with at least one positive culture finding for NTM. All adult non-HIV 
patients from Southern Finland were retrieved from 1990 to the end of 1998 from 
the Microbiological Central Laboratory of Helsinki City, later Helsinki University 
Central Hospital Laboratory (HUSLAB) analyses.
Patients with NTM isolates matched with their medical records by national 
identity code. Data of records collected on paper retrospectively from hospital 
archives at Helsinki University Central Hospitals Meilahti, Peijas, Porvoo, and 
Laakso Helsinki city Hospital. Data of each patient was collected from a period of 
at least 4 years from the first culture positive NTM finding and the date of death 
was ascertained from the Population Register Centre records at 8 June 2006. The 
collected population consisted of 121 patients and patient data on paper format 
collected to electronic format. One patient with a positive finding of both tuberculosis 
and M. avium, was excluded. After exclusion, a total of 120 patients were identified 
(Table 4.1).
Study III included both study I–II and study IV patients with NTM. Study III 
based on retrospective laboratory-based surveillance data on 120 NTM mycobacteria 
patients collected from 1990 to the end of 1998 as declared in study I-II above. Their 
survival was followed until 8 June 2006. A prospective data was collected of study 
IV population of 50 NTM patients with at least one positive NTM finding, collected 
from 2004 to the end of 2009 among patients, who were admitted to the Division 
of Lung Disease or to the Division of Infectious Diseases, at Helsinki University 
Central Hospital clinics. Patients matched with their medical records by national 
identity code and patient data was collected retrospectively in electronic and paper 
format. The medical records of these patients were reviewed and survival followed 
until 31 December 2011. The date of death was ascertained from patients’ records 
or the Population Register Centre records. The collected population consisted of 
120 retrospectively collected patients (study I–II) and 50 prospective NTM patients 
(study IV). Two of the 50 prospective NTM patients were excluded as they were 
already included in the 1990–98 study group and one patient of 50 prospective 
NTM patients was excluded due to negative culture findings. After exclusion, a total 
of 167 patients were identified (Table 4.1).
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Table 4.1. Patients with NTM study design and data collection.
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Study IV comprised adult patients at Helsinki University Central Hospital, Division 
of Lung Diseases or Division of Infectious Diseases with a NTM isolation. Data 
from patients with a M. tuberculosis isolation will also be presented in this thesis 
(unpublished), which was not included in published Study IV. Complement C4 
and immunoglobulin levels in NTM and MTB patients will be presented (IV and 
unpublished results).
Patients who were admitted to these clinics with at least one positive culture 
with NTM or Mycobacteria tuberculosis finding, were eligible between August 
2004 and December 2009. Out of 257 patients with a NTM isolation, 52 patients 
were recruited, and out of 180 patients with a M. tuberculosis finding, 32 patients 
were recruited. Two NTM patients were excluded due to missing consent. One MTB 
patient was excluded because of a missing laboratory specimen. After exclusion 
criteria were enforced, 50 patients with NTM and 31 patients with Mycobacteria 
tuberculosis were included to study IV (Table 4.1).
In study IV, patients were excluded when they were pregnant, handicapped, 
prisoners, under 18 years-of-age, conscripts, and if they had HIV or CVI (common 
variable immunodeficiency). 
The control cohort (n = 149) consisted of healthy 100 females and 49 males, 
who had been recruited in a health survey from Helsinki region and used in a 
previous study (Seppänen M, Suvilehto J, Lokki M-L, Notkola I-L, Järvinen A, et 
al. (2006) Immunoglobulins and complement factor C4 in adult rhinosinusitis. Clin 
Exp Immunol 145: 219–227). The Ethics Committee of the Department of Medicine, 
Hospital District of Helsinki and Uusimaa approved the study.
4.2 ETHICS
Patients gave written informed consent for study IV and The Ethics Committee of 
the Department of Medicine, Hospital District of Helsinki and Uusimaa approved 
all study protocols (I–IV). Permissions were acquired from the Ministry of Social 
Affairs and Health to retrieve patient records outside the Helsinki University Central 
Hospital (Studies I–III).
4.3 DATA COLLECTION 
Study I–II. Data from the patient records collected on the paper form. Relevant 
patient data reviewed at the time of the first positive NTM culture and at patient 
visits closest (+/- 6 months) and 1, 2, and 4 year thereafter.
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At the time of the first positive NTM culture and patient visit (+/- 6 months), 
the following patient data was collected. Demographic characteristics (gender, age, 
body weight, height, occupation) were collected. Data on smoking habits were 
retrieved from both the medical records and pulmonary function test questionnaires. 
Alcohol abuse was retrieved from medical records. Underlying pulmonary diseases 
(bronchiectasis, COPD, prior tuberculosis, lung fibrosis, asthma, other pulmonary 
disease, pulmonary or other malignancy, no previous pulmonary diseases) were 
collected. Further other underlying diseases (sinusitis, scoliosis or thoracic 
abnormality, hypertonia, coronary artery disease, atrial fibrillation, myocardial 
infarction, palpitation, systemic corticosteroid treatment over 1 month, inhalation 
steroid treatment over 1 month, immunosuppressive therapy) were collected. 
Concomitant (underlying) diseases were classified as described by McCabe and 
Jackson (McCabe and Jackson 1962), as follows: (1) healthy, i.e. no other diseases; 
(2) chronic non-fatal diseases; (3) ultimately fatal diseases with a life-expectancy of 
5 y maximum, such as carcinoma with local spreading and uncompensated hepatic 
cirrhosis; (4) rapidly fatal diseases with expected survival of no more than 6 months, 
such as carcinoma with widespread metastases.
Pulmonary symptoms (cough, dysphnea, haemothpysis) and systemic symptoms 
(fatigue, fever >37.5 ° C, weight loss, decreased appetite, night sweats, lymphadenitis, 
skin nodules) were collected.
From the microbiological findings, the numbers of subsequent NTM positive 
or negative mycobacterial smears, cultures, and sampling sites were recorded. 
Other laboratory findings (hemoglobin, hematocrit, thrombocytes, leukocytes, 
lymphocytes, eosinophils, CRP, sedimentation rate, creatinine, ALT, AST, alkaline 
phosphatas) were all reviewed at the time of first positive NTM culture.
The radiological findings of chest X-ray and CT scans were collected from the 
original radiologist’s statements relevant to ATS criteria and classified as infiltrates, 
nodules, cavities, or bronchiectasis according to the 2007 ATS criteria. Further 
pulmonary function tests (FVC %, FEV 1 %, MEF 50 %) were collected.
During retrospective surveillance, data was collected from 1, 2, and 4 years 
following the first positive NTM culture. Similarity patient symptoms, the 
microbiological data, the radiological findings, pulmonary function tests and 
smoking habit were reviewed and collected at the time of 1, 2 and 4 years during 
patient visit (+/- 6 months). 
Concurrent medication and the previous (6 months) immunosuppressive 
treatments were reviewed. Systemic or inhalation corticosteroid treatment 
was recorded when continued for longer than 1 month. The anti-mycobacterial 
medication and the results of in vitro sensitivity tests were recorded. The use of 
at least 2 potentially effective agents, based on the existing literature, for at least 3 
months was required to classify the patient as having received anti-mycobacterial 
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medication treatment. Therefore, the anti-mycobacterial medication was categorized 
into the following subgroups: (1) less than 3 months; (2) 3–5 months; (3) 6–11 
months; (4) 1–2 y; (5) 2–3 y; (6) at least 3 y (I-II).
According to symptoms, microbiological, and radiological findings, the patients 
were classified according to the 2007 ATS (Griffith et al. 2007) NTM case definition 
into positive and negative groups (Table 4.2).
Table 4.2. Patients with NTM and ATS 2007 criteria positive definitions (Griffith et al. 2007).
Symptoms compatible with NTM
Pulmonary symptoms: Cough, dyspnoea, haemoptysis.
Systemic symptoms: Fatigue, fever >37.5 °C, weight loss, 
decreased appetite, night sweats, lymphadenitis, skin 
nodules. 
 Microbiological criteria
At least 2 separate positive sputum cultures,
or
1 positive culture from a bronchoscopic sample (lavage or 
brush) 
or
from transbronchial/ other lung biopsy with mycobacterial 
histopathologic features (granulomatous inflammation or 
AFB) and positive culture for NTM
or
biopsy showing mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and one or more 
sputum or bronchial washings that are culture positive for 
NTM.
One positive culture from a skin or lymphatic tissue biopsy.
Radiological criteria
Nodular or cavitary opacities on chest radiographs
or 
bronchiectasis with multiple small nodules on CT/ HRCT
and
appropriate exclusion of other diagnoses.
Study III. Data from study I–II patients was collected at the time of the first positive 
NTM culture (+/- 6 months) and one year thereafter as described above (I–II). From 
study IV, NTM patient records were collected on the electronic form and reviewed at 
the time of the first positive NTM culture and at patient visits closest (+/- 6 months) 
and one year thereafter. Relevant patient data for demographic characteristics, 
smoking habits and alcohol abuse data collected. The microbiological data (NTM 
positive or negative mycobacterial smears, cultures, and sampling sites) were 
recorded. Other laboratory findings, and pulmonary function tests were reviewed 
at the time of positive NTM culture and at patient visits closest (+/- 6 months) to 
one year thereafter. Further, the radiological findings of chest X-ray and CT scans 
were collected at the time of positive NTM culture and at patient visits closest (+/- 6 
months) to one year thereafter.
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Concomitant underlying diseases were categorized as decribed for study 
I–II (McCabe and Jackson 1962). According to symptoms, in addition to NTM 
microbiological and radiological findings, patients were classified according to the 
2007 ATS NTM case definition into positive and negative groups (Griffith et al. 
2007).
In Study IV, peripheral blood samples of 35 ml were drawn from patients with 
NTM and MTB on average during one month of admission to hospital before 
any antimycobacterial therapy. Plasma and serum were stored frozen at -70oC 
until analyzed. Data from patients with NTM and MTB, including demographic 
characteristics, underlying diseases classified according to McCabe and Jackson 
(McCabe and Jackson 1962), symptoms, laboratory findings, and radiological 
examinations, were reviewed at the time of recruitment or closest +/-6 months. 
NTM patients categorized to the 2007 ATS criteria NTM case definition into positive 
and negative groups (Griffith et al. 2007) (Table 4.2).
4.4 DEFINITIONS 
4.4.1 NTM INFECTION AND DISEASE ACCORDING TO ATS CRITERIA 2007
In study I–IV, NTM isolation was defined as NTM infection if patients had at least 
one positive NTM culture finding from sputum, pulmonary, extarpulmonary, or 
blood isolate specimens. 
In study I–IV, NTM infection was defined as NTM disease if patients were ATS-
positive, fulfilling the ATS criteria 2007 from the first positive NTM culture isolation 
within 1 year of surveillance. Otherwise the patient was categorized as ATS-negative 
(Table 4.2). Fever was defined when axillary temperature was over 37.5 ⁰C. Weight 
loss was defined at least 5 kg in 6 months. BMI was defined as underweight when 
less than 18.5 kg /m2 and 18.5–24.9 kg /m2 was defined as normal and over 25.0 
kg /m2 was defined as overweight. In study I, (smoking) patients were divided 
into non-smokers (those who had never smoked) and smokers (those who were 
previous or current smokers). Four patients whose smoking history was unclear 
were categorized as smokers, because probably they have been ex-smokers in their 
youth according to patient data. Occupations were divided to blue and white collar. 
The blue collar included farmers, fishermen, vendors, and industrial workers and 
the white collar included civil servants, office workers, enterprise, business, and 
industrial administration personal.
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4.4.2 C4 DEFICIENCY ANALYSES 
In study IV, patients with NTM infection or with NTM disease had C4 deficiency 
if C4 deficiency was exposed less than two copies of C4A or C4B.
4.4.3 RADIOLOGICAL FINDINGS
The chest X-ray and CT scan findings were classified as infiltrates, nodules, cavities, 
or bronchiectasis. Further, the findings were categorized to each lobe of the lungs 
separately, or to diffuse findings in both lungs.
4.4.4 LABORATORY FINDINGS
CRP was defined as elevated when over 10 mg/ml. Sedimentation rate was elevated 
when over 20 mm/h. Leukocytosis was defined elevated if white blood counter was 
over 12 x 109./L. Thrombocytopenia was defined to be when blood platelet count 
was less than 100 x 109 /L. Alanine aminotransferase (ALT) > 120 U/L in females 
and > 150 U/L in males, aspartate aminotransferase (AST) >120 U/L in females 
and > 150 U/L in males, and alkaline phosphatase >300 U/L were defined as 
elevated liver enzyme conditions. Haemoglobin lower than 120 g/L was defined 
as anemia. In pulmonary function tests, FVC % (forced vital capacity, % from the 
predicted value) was defined as obstruction when less than 80%. FEV 1% (forced 
expiratory volume in 1 s, % from the predicted value) was defined as obstruction 
when less than 80%. MEF 50% (maximum mid-expiratory flow rate, measured 
during expiration of 50% of the vital capacity, % from the predicted value) was 
defined as obstruction when less than 62% (Sovijärvi 2011).
4.5 MICROBIOLOGICAL METHODS
4.5.1 IDENTIFICATION OF MYCOBACTERIA
In study I–IV, patient findings for NTM were detected by the Central Microbiology 
Laboratory of Helsinki City, later Helsinki University Central Hospital Laboratory 
(HUSLAB). Clinical samples, except blood samples, were stained with auramine-O-
fluorochrome dye and examined microscopically for acid-fast bacilli (AFB). Cultures 
positive for acidfast bacilli were identified by conventional biochemical tests and 
hybridization with DNA probes (AccuProbe; Gen-Probe, San Diego, CA, USA). 
Cultures negative for Mycobacterium tuberculosis and MAC complex were identified 
by amplification and sequencing of the 16S rRNA gene. Those NTM patients with 
a positive culture finding for NTM from 2004 to the end of 2009, cultures positive 
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for acid-fast bacilli were identified by DNA strip assays (GenoType Mycobacterium 
CM/AS, Hain Lifescience, Nehren, Germany). Nomenclature was changing during 
the study period and for that reason MAC, M. avium, and M. intracellulare were 
all classified as MAC.
4.5.2 IDENTIFICATION OF C4 DEFICIENCY
Blood samples for immunoglobulin, the deficiencies of complement, C4A and C4B 
gene copy numbers, and phenotype frequencies of the C4 allotypes were analyzed. 
The numbers of C4A and C4B genes and allotypes of C4A and C4B proteins were 
determined, as previously published (Paakkanen et al. 2012), in the HLA Laboratory 
with international EFI-accreditation (European Federation for Immunogenetics) a 
division of the Transplantation Laboratory at the Haartman Institute, University 
of Helsinki. All samples were kept frozen at –70°C. Out of C4A genes, CT insertion 
(a C4-silencing mutation), was reduced. Less than two copies of C4A or C4B was 
defined as C4 deficiency.
4.5.3 IDENTIFICATION OF LOW IMMUNOGLOBULIN LEVELS
Levels of IgA, IgM, IgG, and IgG subclasses, C3, C4 levels and CH100 were 
ascertained.
Plasma IgA, IgM, IgG (Dade Behring BN ProSpec, Marburg, Germany), and 
IgG subclasses 1–4 (PeliClass BN, Sanquin Reagents, Amsterdam, the Netherlands) 
were measured by nephelometry according to the manufacturers’ instructions. We 
used the manufacturer’s reference values for levels below two standard deviations 
from the mean to define low immunoglobulin levels. 
Plasma concentrations of C4, C3 (Behringwerke AG, Marburg/Lahn, Germany), 
and CH 100 (Quidel Corporation, San Diego, CA, USA) were analyzed. Low 
immunoglobulins were defined as Ig G < 6.8.g/l, IgM < 0.6 g/l, IgG1 < 4.9g/l, 
IgG2< 1.5g/l , IgG3<0.2g/l, IgG4<0.08g/l. Low complements were defined as C3 
< 0.50 g/l, C4< 0.12g/l, CH100 < 74%. 
4.6 STATISTICAL METHODS
Study I–III.
Patient groups were compared using the independent samples t -test for continuous 
variables. Variables that were skewed to the right were logarithmically (ln) 
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transformed before analysis (I-II). Mann-Whitney U test was used if the assumption 
of normality was not achieved using transformations (Study III). The Chi-squared 
test and Fisher’s exact test were used to analyse the dichotomous variables. 
The Kaplan–Meier method was used to estimate the median survival times with 
95% confidence intervals (CI).
Cox regression multivariable analyses were performed to adjust the survival 
times for other explanatory factors (CI) (I). The forward stepwise multivariate Cox 
proportional hazards model was run to find the most important prognostic factors 
and stepwise model as potential explanatory variables and third, adjusted survival 
time comparisons were performed using 2 multivariate Cox proportional hazards 
models (II). The univariate Cox proportional hazards model was used to compare 
the survival times. The forward stepwise (criterion for entry p<0.05) multivariate 
Cox proportional hazards model for explanatory variables (III). All results were given 
as hazard ratios (HR) with 95% confidence intervals. Study I data were analyzed 
using SPSS statistical software (version 15.0; SPSS Inc., Chicago, IL USA), study 
II using SPSS statistical software (version 17.0; SPSS Inc., Chicago, IL, USA) and 
study III data using IBM SPSS Statistics for Windows (version 21.0, Armonk, NY, 
USA, IBM Corp).
Study IV. 
All statistical tests were performed using IBM SPSS statistics software (version 20, 
NY). Differences in proportions between groups were tested by the Chi-square test 
or by Fisher’s exact two tailed test, according to which was appropriate. Continuous 
variables that were not normally distributed were transformed as such by using 
logarithmic transformation. The continuous variables were compared using the 
Student’s t-test. Laboratory parameters were assessed as continuous variables and 
as abnormal values, according to the reference values of the performing Laboratory 
(HUSLAB).
The Mantel-Haenszel method and the Breslow-Day test were used to test 
the homogeneity of the odds ratios between males and females. The sample size 
calculation was based on the prevalence previously reported; 58% prevalence of 
C4 deficiency in healthy controls and an assumption of C4 deficiency in 80% of 
NTM patients (Seppänen et al. 2006). A two group c2 test with a 0.05 two-sided 
significance level will have 80% power to detect the difference between these 
prevalences (odds ratio of 2.90) resulted in sample sizes of 47 NTM patients and 
141 healthy controls, respectively. P-values of < 0.05 were considered statistically 
significant.
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5 RESULTS 
5.1 DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH A 
NTM ISOLATION (I–III) 
The demographic characteristics of the patient population in Studies I–III are 
shown in Table 5.1.1. The average age of patients was 66 years and there was no 
difference in age between patients with MAC or other isolated NTM. No difference 
was seen in the age of non-smokers and smokers, but ATS-negative patients were 
significantly older than ATS-positive patients (70 vs 63 years; p= 0.003, I–II, Table 
5.1.1). Whereas smoking did not differ between ATS-negative and -positive patients 
smoking was significantly more common in patients with other NTM (61%) than 
in MAC group (61% vs 42%, p= < 0.001, II, III, Table 5.1.1). 
In total, 55% of all NTM patients were female. There was a significant 
overrerpresentation of female gender among non-smokers, ATS-positive, and MAC 
patients as compared to smokers, ATS-negative, and other NTM patients (I–III, 
Table 5.1.1). BMI was on an average 21.3 ± 4.2 (kg/m2, mean ± SD) among all NTM 
patients. Patients with MAC were significantly leaner as compared to patients with 
other NTM (20 vs 23 BMI, p= 0.001, III, Table 5.1.1). 
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Table 5.1.1. Characteristics of 167 patients with non-tuberculous (NTM) isolation categorized according to 
smoking (Study I), ATS 2007 criteria fulfilment (Study II), and MAC vs other NTM (Study III) (Studies I–III).
Age 
Mean (SD)
cBMId
Mean (SD) 
Female Alcohol 
abuse 
Non-
smoker
ATS 
2007 
positive
nb years kg/m2 % % % %
Study I
Non-smokers 50 64.1 (17.3) 19.9 (3.0) 72 0 42 58
Smokers 70 68.0 (10.5) 21.4 (4.2) 30 17 0 46
Total 120 66.4 (13.8) 20.8 (3.8) 48 10 42 51
pa 0.156c 0.061 <0.001c 0.001e 0.184a
Study II
ATS 2007 Positive 61 62.7 (15.0) 20.3 (3.1) 57 7 48 100
ATS 2007 
Negative 59 70.1 (11.3) 21.3 (4.5) 37 14 36 0
Total 120 66.4 (13.8) 20.8 (3.8) 48 10 42 51
pa 0.003 0.24 0.03 0.20 0.18
Study III
MAC 99 65.6 (14.4) 20.3 (3.7) 70 5 58 61
Other NTM 68 66.7 (13.3) 22.9 (4.3) 34 12 29 49
Total 167 66.0 (13.9) 21.3 (4.2) 55 8 46 56
pa 0.624c 0.001c <0.001a <0.001a 0.123a
a Chi-squared test
b Values are expressed as n (%), unless otherwise stated
c t-Test for independent samples
d BMI, body mass index kg/m²
e Fisher’s exact test.
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Results 
5.2 UNDERLYING DISEASES AMONG PATIENTS WITH A NTM 
ISOLATION (I–III)
Patients who were non-smokers, ATS positive, or had MAC had significantly 
less fatal underlying diseases as compared to smokers, ATS negative, and other 
NTM, respectively (I–III, Table 5.2.1). In total, 67% of all NTM patients lacked 
any potentially fatal underlying diseases (III, Table 5.1.2). Bronchiectasis was 
significantly more common among non-smokers (28%) and MAC patients (25%) as 
compared to smokers (4%) and other NTM patients (5%), but there was no difference 
in bronchiectasis according to ATS criteria fulfillment (I–III, Table 5.2.1). Only 25% 
of all NTM patients had no previous pulmonary diseases with no difference according 
to smoking history or ATS criteria fulfillment (III, Table 5. 2.1). While 25% of ATS-
negative patients had a history of asthma, only 10% of ATS-positive patients were 
asthmatic (p = 0.02) but no difference in previous asthma was observed according 
smoking status or NTM strain (I–III, Table 5.2.1). 
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Table 5.2.1. Underlying diseases in 167 patients with non-tuberculous (NTM) isolation categorized according to smoking, 
ATS 2007 criteria fulfilment and MAC vs other NTM strain.
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Study I
Non-smokers 50 82 18 28 4 16 8 18 26 12 28 22 16
Smokers 70 59 41 4 43 26 17 17 23 23 19 30 17
Total 120 68 32 14 27 22 13 18 24 18 23 27 17
pa 0.007 <0.001 <0.001 0.203 0.146 0.903 0.692 0.130 0.223 0.329 0.868
Study II
ATS 2007 
Positive 61 77 23 18 20 16 10 10 33 16 26 20 11
ATS 2007 
Negative 59 59 41 10 34 27 17 25 15 20 19 34 22
Total 120 68 32 14 27 22 13 18 24 18 23 27 17
pa 0.04 0.22 0.08 0.15 0.25 0.02 0.02 0.58 0.32 0.08 0.12
Study III
MAC 99 77 23 25 23 16 8 14 16 12 27 26 27
Other NTM 68 53 47 7 31 19 13 16 28 22 23 27 13
Total 167 67 33 18 26 17 10 15 21 16 25 26 21
pa 0.001a 0.003a 0.270a 0.620a 0.279a 0.717a 0.066a 0.087a 0.846a 0.043a
a Chi-squared test (or t-test for independent samples
b Values are expressed as n (%), unless otherwise stated.
c Underlying diseases classified according to the criteria of McCabe classification (McCabe and Jackson 1962) :
1) healthy i.e. no other diseases
2) non-fatal chronic diseases
3) ultimately fatal diseases with expected life expectancy of maximally 5 years (i.e. carcinoma with local spreading)
4) rapidly fatal diseases with expected survival for no more than 6 months (i.e. carcinoma with wide spread metastases
d COPD, chronic obstructive pulmonary diseases.
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Results 
5.3 SYMPTOMS AT THE TIME OF NTM ISOLATION (I–III)
All patients had symptoms suitable for NTM infection at the time of NTM isolation. 
In almost half (48%) of the patients’ symptoms had appeared during the year before 
a positive NTM culture finding (I–II, Table 5.3.1). Patients with other NTM had 
symptoms for a shorter time as compared to patients with MAC (54% vs. 34%, p= 
0.001, III, Table 5.3.1). 
Fatigue was significantly more common in ATS-positive patients than in ATS-
negative patients (56% vs. 37%, p= 0.04, II, Table 5.3.1). Fever was significantly 
more common among MAC than other NTM patients (48% vs. 31%, p = 0.023, III, 
Table 5.3.1 ). Instead there was no difference in the occurrence of various symptoms 
between the groups divided according to smoking status, ATS criteria fulfillment, 
or MAC vs. other NTM (I-III, Table 5.3.1) like cough, which was the most common 
symptom and it was reported by two thirds of all patients (III) and dyspnoea, the 
second most common symptom, which occurred in about half of the patients (III). 
About one fifth of the patients had haemoptysis and about one third experienced 
weight loss, whereas non-specific general symptoms like night sweats were fairly 
uncommon (I–III, Table 5.3.1). Clinically the early presenting symptoms were cough, 
dyspnoea upon physical exercise and fatigue, but we did not analyze the appearance 
order or time of different symptoms .
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Table 5.3.1. Symptoms and signs at the time of the first positive NTM isolation from 167 patients. 
Duration of symptoms Respiratory symptoms Nonspecific symptoms
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Study I
Non-
smokers 50 50 22 16 12 76 52 28 54 46 36 16 6 8 16
Smokers 70 46 36 6 12 73 51 21 41 39 30 16 4 3 14
Total 120 48 30 10 12 74 52 24 47 42 33 16 5 5 15
pa 0.194c 0.698d 0.951d 0.407d 0.174d 0.416d 0.489d 0.966d 0.693d 0.233d 0.795
Study II
ATS 2007 
Positive 61 47 36 8 8 75 51 21 56 48 36 11 8 7 13
ATS 2007 
Negative 59 48 24 12 16 73 53 27 37 36 29 20 2 3 17
Totalf 120 48 30 10 12 74 52 24 47 42 33 16 5 5 15
pa 0.17c 0.75 0.85 0.46 0.04 0.18 0.40 0.18 0.21d 0.68d 0.56
Study III
MAC 99 34 36 18 12 80 54 25 47 48 3 12 7 4 14
Other 
NTM 68 54 26 15 4 72 47 19 32 31 25 13 1 6 15
Total 167 43 32 16 9 77 51 23 41 41 29 13 5 5 14
pa 0.01c 0.245 0.411 0.353 0.051 0.023 0.307 0.831 0.144d 0.717d 0.91
a Chi-squared test
b Values are expressed as, n (%) of patients with valid information unless otherwise stated.
c The categories were combined (£2 years vs. ³3 years) before analysis (Study I, II).
c The categories 1-2 y, 3-10 y and > 10 y were combined before analysis (Study III). 
d Fisher’s exact test.
f Missing information: Study II: 3 patients (ATS 2007 positive two patients, ATS 2007 negative one patients.),
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5.4 MICROBIOLOGICAL FINDINGS (I-III) 
Of all 167 patients, MAC was found in 60% (III). It was found in 72% of non-smokers 
and 41% of smokers (p = 0.001), but no difference was observed according to ATS 
criteria fulfillment; 61% of isolates in ATS 2007 positive and 47% in ATS 2007 
negative patients (p = 0.15, II). 
Of the 167 NTM patients, combinations of two different strains were cultured 
from five patients. These patients were recorded in accordance with their first isolated 
strain. Patients with these combinations were as follows: MAC + M. malmoense, 
M. avium +M. lentiflavum, M. intracellulare + M. fortuitum, M. abscessus + M. 
fortuitum, and M. triplex + M. gordonae. 
Smears were negative for a total of 62% of the all patients. A positive sputum 
culture was obtained from 145 patients out of all 167 patients. NTM was cultured 
from pulmonary biopsy from seven patients and from bronchoscopic samples from 
five patients. In four patients, positive NTM culture was found only in a culture 
from a lymph node (MAC) or blood (M. chelonae). Skin culture was positive in six 
patients: two patients had M. marinum and four patients had RGM.
After the first positive NTM culture, a subsequent second positive culture was 
obtained in 54% of non-smokers and 51% of smokers, in 80% of ATS 2007 positive 
patients but only in 22% of ATS 2007 negative patients during the following year 
(Study I Table IV, Study II Table IV). 
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Table 5.4.1. Microbiological findings in 167 patients with at least one NTM culture positive isolation
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Study I
Non-smokers 50a 72 28 8 4 2 0 2 8 2 0 2 0 0
Smokers 70a 41c 59 11 13 6 1 1 17 0 3 0 1 4
Total 120a 54 10 9 4 1 2 13 1 2 1 1 3
Study II
ATS 2007f 
Positive 61
a 61c 39 13 5 5 2 2 5 2 2 2 0 3
ATS 2007f 
Negative 59
a 47 53 7 14 3 0 2 22 0 2 0 2 2
Total 120a 54 46 10 9 4 1 2 13 1 2 1 1 3
Study III
MAC 99 59
Other NTM 68 - 41 22 21 9 23 6 24 3 3 2 2 7
Total 167 59 41 9 8 4 1 2 10 1 1 1 1 3
a Values are expressed as n (% within each group)
b MAC, Mycobacterium avium complex; NTM, non-tuberculous mycobacteria
b MAC includes M. avium, M.avium complex and M. intracellulare
c p = 0.001 as compared to non-smokers, Chi-squared test.
c p=0.15 as compared to negative ATS 2007, Chi-squared test
d skin infection
f ATS, American Thoracic Society.
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5.5 RADIOLOGICAL FINDINGS (I–III) 
Only one smoker had a normal chest X-ray, whereas all other patients who had an 
X-ray taken had findings suitable for NTM infection. Computer tomographies were 
performed for 55% of the patients and all demonstrated findings related to NTM 
disease. Nodules and bronchiectasis were significantly more common among non-
smokers, ATS positive patients, and in MAC patients as compared to smokers, ATS 
negative patients, and other NTM patients, respectively (I-III, Table 5.5.1). Infiltrates 
were found in 30–40% of patients in groups without significant differences between 
the groups (I–III, Table 5. 5.1). Cavities were a rare finding and they were observed 
in only 8% of patients (III, Table 5. 5.1). 
The radiological findings were most common in right upper (35% of patients) 
and right middle lobes (27%), but they were also observed in all other parts of 
the lung (left lower lobe in 21%, right lower lobe in 17%, left upper lobe in 16% of 
patients) (I–III, Table 5. 5.1). No difference was seen in the localization of radiological 
changes between the groups, but diffuse findings were more common in MAC (29%) 
compared to other NTM (15%) patients (III). 
Pulmonary function tests were made only on 53–60% of patients in the various 
studies. Obstructive impairment observed as a decreased FEV 1% and MEF 50% 
but no differences between the groups in pulmonary function tests were found 
(Study I Table V, Study II Table V).
CRP level was elevated in 90% of patients and ESR (mm/h) was elevated in 84% 
of patients without differences between the patient groups (Study I Table V, Study 
II Table V). Haemoglobin was an average normal without clear anemia (Study I 
Table V, Study II Table V). Leukocyte count was an average close to upper normal 
limit (Study I Table V, Study II Table V).
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Table 5.5.1. Radiological findings during the first year after NTM isolation categorized according to smoking, the ATS 2007 criteria 
fulfillment and MAC vs other NTM
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Study Ig
Non-smokers 50 84 50 33  33  10 31 21  13  21 21  35  27 
Smokers 70  91  41 38 7 4 6 37  22  27 13  21  15
Total 120 88  45 36 18 7 16 30  18  24  16  27  20 
pa 0.211 0.352 0.630 <0.001 0.270f <0.001 0.066 0.188 0.485 0.276 0.075 0.100
Study II
ATS 2007 
Positive 61  92  59 42 27 12  23 33  15  26  21  28  21 
ATS 2007 
Negative 59  88 30 30 9 2 9 27  22 22 11 26  18
Total 120  90 45  36 18 7  16  30  18 24 16 27  20 
pa 0.46c 0.002 0.18 0.01 0.06f 0.03 0.52 0.32 0.58 0.13 0.77 0.67
Study III
MAC 99 94 56 42 34 10 31 38 14 28 18 21 29
Other NTM 68 90 53 40 12 6 13 31 19 25 15 22 15
Total 167 92 55 41 26 8 24 35 16 27 17 21 23
pa 0.842 0.003 0.478 0.009 0.417 0.315 0.697 0.638 0.812 0.034
a Chi-squared test
b Values are expressed as n (%) of patients with valid information
d CT, computer tomography, 
e Multiple locations were possible
f Fisher’s exact test
g Missing information I-II: Radiographical examinations 2 patients. Radiographical findings 3 patients. Location of 
radiographical findings: 4patients
h Missing information study III: Radiographical findings: 6 MAC patients, 6 other NTM patients ( no x-ray 12 patients). 
Location of radiographical findings: 4 patients.
i No-x-ray 11 patients Study I-II (Study I: 7 non-smokers and 4 smokers. Study II: 5 ATS –positive and 6 ATS -negative). No- 
x-ray 12 patients Study III (6 MAC and 6 other NTM patients).
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5.6 PROGNOSTIC FACTORS 
5.6.1 SMOKING AS A PROGNOSTIC FACTOR (I)
Smokers had a significantly higher risk of death as compared to non-smokers (HR 
1.64, 95% CI 1.00–2.69, p = 0.049, Study I, Figure 1, panel A). The median survival 
time for non-smokers was 155 months (=12.9 years) which was significantly longer 
than that for smokers (64 months i.e. 5.3 years) (p =0.047, Study I, Figure 1) and 
(Table 5.6.1). Severe underlying diseases (McCabe classes 3–4) were found to be 
the most important predictor of mortality (HR 4.69, 95% CI 2.82–7.79, p < 0.001, 
Study I, Figure 1, panel C). After adjusting for underlying diseases, smoking was 
not significantly associated with higher mortality (HR 1.18, 95% CI 0.71–1.97, p 
= 0.529, Study I, Figure 1, panel C). The median survival time for smokers with 
McCabe classes 3–4 was only 1.7 years as compared to 2.0 years in non-smokers 
with McCabe classes 3–4 (I, Table 5.6.1).
5.6.2 ATS 2007 CRITERIA AS A PROGNOSTIC FACTOR (II)
ATS 2007 criteria fulfillment was not observed to be a significant predictor of 
fatal outcome. The median survival time for ATS-positive patients was 7.4 years 
(95% CI 0.2–14.6) as compared to 5.3 years (95% CI 3.0–7.6) for ATS-negative 
patients (HR 0.68, 95% CI 0.43–1.09, p =0.11, Study II, Figure 1, Table 5.6.1). ATS 
criteria fulfillment was not a significant explaining factor for fatal outcome in the 
multivariate Cox proportional hazards model in which McCabe class was found to 
be a significant predictor for mortality (HR 4.76, 95 % CI 2.90-7.81, p>0.001, Study 
II, Figure 2). Figure 2 (Study II) shows that no difference in mortality was observed 
between the ATS-positive and ATS-negative groups when they were categorized 
according to McCabe classes. The median survival time for patients in McCabe 
classes 3–4 and ATS 2007 criteria positivity was 1.9 (1.5–2.3) years and 1.9 (0.9–3.0) 
years also in ATS 2007 negative patients (HR = 0.82, 95% CI 0.51–1.33, p = 0.42, 
Study II, Figure 2, Table 5.6.1). 
5.6.3 ANTI-MYCOBACTERIAL MEDICATION AS A PROGNOSTIC FACTOR (II) 
Out of all 120 patients (Studies I–II) anti-mycobacterial medication with at least 
2 potentially effective drugs for at least 3 months was given to 60% (72/120) of 
patients. In 57% of patients, the medication was started within 6 months of the first 
NTM isolation. Treatment for 3 months was given to 20% of patients whereas 8% 
of patients received medication for 6 months, 20% for at least 12 months, and 12% 
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for over 12 months. Only 13% of patients who received any medication were given 
drugs that were not effective against the isolated NTM strain. Medication was given 
to 72% (44/61) of ATS-positive and 47% (28/59) of ATS-negative patients (Study 
II). Patients who received antimycobacterial medication in ATS 2007 positive and 
ATS 2007 negative groups did not have a difference in mortality as compared to 
corresponding patients without treatment (HR 1.14, 95% CI 0.69–1.87, p = 0.61, 
Study II, Figure 3, Table 5.6.1).
5.6.4 MAC AS A PROGNOSTIC FACTOR (III) 
The median survival time was 13.0 years (95% CI 5.9–20.1) for all MAC patients 
and 5.2 years (2.3–8.1) for all other NTM patients (III, Table 5.6.1). In the subgroup 
analysis patients with pulmonary MAC had a significantly lower risk of death as 
compared to patients with pulmonary infection due to other NTM [HR 0.50 (95% 
CI 0.33–0.77), p = 0.002, Study III, Fig. 1, panel A] or a subgroup of other slowly 
growing NTM (M. malmonese, M. xenopi, M. paranifficum, M. terrae, M. triplex) 
[(HR 0.55 (95% CI 0.31–0.99), p = 0.048), Study III, Fig.1, panel B] or as rapidly 
growing NTM [(HR 0.47 (95% CI 0.25–0.87), p = 0.02), Study III, Fig. 1, panel 
C]. Median survival time was 13.0 years (95% CI 5.9–20.1) for pulmonary MAC 
patients but 4.6 years (95% CI 3.4–5.9) for pulmonary infections due to other NTM 
(Study III, Fig.1, panel A).
For all patients, when fulfillment of ATS 2007 criteria and fulfillment of MAC 
were predictors in the same multivariate Cox proportional hazards model, the 
survival among the MAC group was significantly higher than that of the other 
NTM group (HR = 0.57, 95% CI 0.37–0.88, p = 0.01, Study III, Fig. 2, panel A). 
Furthermore, survival among the ATS 2007 positive patients tended to be higher 
than among the ATS 2007 negative patients [HR = 0.66, 95% CI 0.44–1.01, p = 
0.06, Fig. 2, panel A] (III, Table 5.6.1.). The effect of ATS 2007 criteria fulfillment 
was non-significant in reducing the mortality risk (HR = 0.66, 95% CI 0.44–1.01, 
p = 0.06, Study III, Fig. 2, panel A). When fatal underlying diseases (McCabe 3–4) 
and fulfillment of MAC were predictors in the same multivariate Cox proportional 
hazards model, the survival among MAC group was significantly higher than in other 
NTM group [HR = 0.65, 95% CI 0.42–1.00, p = 0.048, Study III, Fig.2, panel B], 
(III; Table 5.6.1). The effect of McCabe 3–4 as a risk factor for fatal outcome was 
also significant (HR = 3.33, 95% CI 2.16–5.12, p < 0.001, Study III, Fig. 2, panel 
B, Table 5.6.1).
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Table 5.6.1. Survival of NTM patients (Studies I, II, and III). Results are given in groups according to 
smoking status, ATS 2007 criteria fulfillment, and MAC or other NTM isolation, and further divided into 
subgroups by McCabe classification and treatment with antimycobacterial medication for at least 3 months. 
Survival time 1
(years) Survival rates (%) 1
N Median (95% CI) 1 yr 5 yrs 10 yrs
Study I (Smoking)
 Smoking + 70 5.3 (4.3–6.3) 82.9 54.3 35.1
 Smoking – 50 12.9 (4.8–21.0) 96.0 68.0 56.0
 Overall 120 6.1 (2.9–9.3) 88.3 60.0 43.7
Smoking and ATS 2007
 smoking +  ATS 2007 + 32 5.3 (4.7–5.9) 90.6 59.4 37.2
 smoking +  ATS 2007 – 38 4.6 (1.8–7.4) 76.3 50.0 33.5
 smoking –  ATS 2007 + 29 12.9 * 100.0 75.9 62.1
 smoking –  ATS 2007 – 21 5.9 (0.0–12.0) 90.5 57.1 47.6
Smoking and McCabe
 smoking +  McCabe 1–2 41 15.6 (4.9–26.4) 92.7 78.0 50.5
 smoking +  McCabe 3–4 29 1.7 (1.0–2.4) 69.0 20.7 13.8
 smoking –  McCabe 1–2 41 12.9 * 100.0 78.0 65.9
 smoking –  McCabe 3–4 9 2.0 (1.8–2.1) 77.8 22.2 11.1
Smoking and medication ( >3 mo)
 smoking +  medication – 27 5.6 (4.2–7.0) 81.5 63.0 25.4
 smoking +  medication + 43 4.6 (3.0–6.3) 83.7 48.8 37.2
 smoking –  medication – 21 * 100.0 71.4 52.4
 smoking –  medication + 29 12.9 (4.4–21.4) 93.1 65.5 58.6
Study II (ATS 2007)
 ATS 2007 + 61 7.4 (0.2–14.6) 95.1 67.2 49.1
 ATS 2007 – 59 5.3 (3.0–7.6) 81.4 52.5 38.0
 Overall 120 6.1 (2.9–9.3) 88.3 60.0 43.7
ATS 2007 and smoking
 ATS 2007 +  smoking + 32 5.3 (4.7–5.9) 90.6 59.4 37.2
 ATS 2007 +  smoking – 29 12.9 100.0 75.9 62.1
 ATS 2007 –  smoking + 38 4.6 (1.8–7.4) 76.3 50.0 33.5
 ATS 2007 –  smoking – 21 5.9 (0.0–12.0) 90.5 57.1 47.6
ATS 2007 and McCabe
 ATS 2007 +  McCabe 1–2 47 * 97.9 76.6 59.5
 ATS 2007 +  McCabe 3–4 14 1.9 (1.5–2.3) 85.7 35.7 14.3
 ATS 2007 –  McCabe 1–2 35 10.2 (6.0–14.4) 94.3 80.0 55.2
 ATS 2007 –  McCabe 3–4 24 1.9 (0.9–3.0) 62.5 12.5 12.5
ATS 2007 and medication
 ATS 2007 +  medication – 17 * 100.0 76.5 52.3
 ATS 2007 +  medication + 44 7.0 (0.5–13.6) 93.2 63.6 47.7
 ATS 2007 –  medication – 31 5.9 (3.0–8.7) 83.9 61.3 29.0
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 ATS 2007 –  medication + 28 4.0 (2.5–5.5) 78.6 42.9 42.9
Study III (MAC)
 MAC + 99 13.0 (5.9–20.1) 94.9 73.6 53.8
 MAC – 68 5.2 (2.3–8.1) 82.4 52.7 33.9
 Overall 167 8.2 (5.1–11.2) 89.8 65.1 46.3
Mac and smoking
 MAC +  smoking + 42 7.5 (0.6–14.4) 90.5 69.0 49.2
 MAC +  smoking – 57 * 98.2 77.0 57.1
 MAC –  smoking + 48 4.6 (2.7–6.5) 79.2 47.9 27.6
 MAC –  smoking – 20 12.9 90.0 64.6 52.6
Mac and McCabe
 MAC +  McCabe 1–2 76 * 97.4 80.2 60.2
 MAC +  McCabe 3–4 23 5.3 (1.2–9.4) 87.0 52.2 33.2
 MAC –  McCabe 1–2 36 12.9 (8.0–17.8) 94.4 80.3 50.1
 MAC –  McCabe 3–4 32 1.9 (1.1–2.7) 68.8 21.9 15.0
Mac and medication
 MAC +  ATS 2007 + 60 * 96.7 78.3 55.0
 MAC +  ATS 2007 – 39 10.2 (4.2–16.2) 92.3 66.5 52.2
 MAC –  ATS 2007 + 33 7.4 (3.4–11.3) 93.9 60.2 46.2
 MAC –  ATS 2007 – 35 4.3 (1.4–7.2) 71.4 45.7 21.2
1 Kaplan-Meier method was used to estimate the median survival time and the survival rates at 1, 5, 
and 10 years after the date of NTM diagnosis.
* The median survival time or 95% CI cannot be estimated because high proportion of cases at risk 
are censored.
5.7 COMPLEMENT C4 AND IMMUNOGLOBULIN LEVELS IN NTM 
AND MTB PATIENTS (IV AND UNPUBLISHED RESULTS OF 
MTB PATIENTS)
5.7.1 NTM AND MTB PATIENT CHARACTERISTICS AND MYCOBACTERIAL 
STRAINS 
Complement C4 levels and phenotype and serum immunoglobulin levels in 50 
patients with a NTM isolation were compared to 31 patients with tuberculosis (MTB) 
and to 149 healthy controls. The data from NTM patients and healthy controls has 
been published in Study IV but the results of tuberculosis patients have not been 
published elsewhere. All NTM infection patients (50/81, 62%) were of European 
descent. Forty-four patients had pulmonary NTM infection whereas six had extra 
pulmonary NTM infection. The MTB patient group accounted for 31/81 (38%) of 
the study patients. Of these MTB patients, the pulmonary samples were culture 
positive in 30 patients and a lymphatic node culture positive in the remaining 
one patient. Two MTB patients were of African origin, whereas all others were of 
European descent (Table 5.7.1).
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Results 
There were significantly more females in the NTM patient group (72%) compared 
with the MTB patients (29%). The MTB patients were predominantly male and 
significantly younger than patients of the NTM group (Table5.7.1). Notably, NTM 
patients had a higher incidence of ultimately or rapidly fatal disease than the MTB 
patients (McCabe classes III–IV, 18/50[36%] vs. 3/31 [10%], respectively, p = 0.009, 
Table 5.7.1). The NTM patients had a higher incidence of bronchiectasis than the 
MTB patients (15/50 [30%] vs. 3/31 [10%], p = 0.032). The NTM patients showed 
a significantly higher proportion of rheumatoid arthritis (8/50 [16%] vs. 0/31[0%], 
p = 0.021, Table 5.7.1) than MTB patients.
MAC comprised 36/50 (72%) and RGM (M. fortuitum, M. chelonae, M. 
abscessus) was found in (6/50) 12% of all NTM isolations. M. xenopi was found 
in two patients, and M. malmoense in three patients. Other NTM had two patients 
and M. marinum was found in one patient. NTM and M. tuberculosis (MTB) 
concomitant infections were not found. All 31 MTB patients were Mycobacterium 
tuberculosis culture positive and 24 were also sputum smear positive.
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Table 5.7.1. Characteristics and underlying diseases of 81 patients with a nontuberculous mycobacteria 
(NTM) or Mycobacterium tuberculosis (MTB) isolation. The data only partly published in Study IV Values 
are expressed as no (%) of patients with valid information unless otherwise stated.
NTM
n=50
MTBd
n=31
Totald
n=81 p a
no. (%) no. (%) no. (%)
Age median (IQR) yr
65  
(23–90)
50  
(19–80) <0.001
Female 36 (72) 9 (29) 45 (56) <0.001
Pulmonary mycobacterial infection 44 (88) 30 (97) 74 (91) 0.077 b
Mycobacterial infection in lymph nodes 1 (2) 1 (3) 2 (2) 1.00 b
Mycobacterial infection cutaneous 5 (10) 0 (0) 5 (6) 0.151 b
Underlying diseases c
 Healthy or non-fatal diseases (1–2) 32 (64) 28 (90) 60 (74) 0.009
 Ultimately or rapidly fatal diseases (3–4) 18 (36) 3 (10) 21 (26)
Underlying pulmonary diseases
Bronchiectasis 15 (30) 3 (10) 18 (22) 0.032
COPD 13 (26) 7 (23) 20 (25) 0.729
Prior tuberculosis 3 (6) 5 (16) 8 (10) 0.249 b
Asbestosis 2 (4) 3 (10) 5 (6) 0.366 b
Pulmonary fibrosis 1 (2) 0 (0) 1 (1) 1.00f b
Asthma 4 (8) 2 (6) 6 (7) 1.00 b
Pulmonary or other malignancy 6 (12) 2 (6) 8 (10) 0.704 b
No previous pulmonary diseases 16 (32) 13 (42) 29 (36) 0.365
Rheumatoid arthritis 8 (16) 0 (0) 8 (10) 0.021b
Other autoimmune disease 3 (6) 0 (0) 3 (4) 0.282 b
a Chi-squared test for MTB vs NMT.
b Fisher ’ s exact test. 
c Underlying diseases classified according to the criteria of the McCabe classification (viitetiedot): 
1) healthy i.e. no other diseases
2) non-fatal chronic diseases
3) ultimately fatal diseases with expected life expectancy of maximally 5 years
4) rapidly fatal diseases with expected survival for no more than 6 months. 
d Unpublished MTB patients data
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Results 
5.7.2 COMPLEMENT ANALYSES 
C4 deficiency (C4A or C4B) was more common among the NTM patients than 
healthy controls (36/50 [72%] vs 83/149 [56%], OR = 2.05, 95% CI = 1.019–4.105, 
p = 0.042). C4 deficiency was also more prevalent in the NTM patients than in 
the MTB patients 36/50 [72%] vs 11/31 [35%], OR=4.071, 95% CI=1.574–10.533, 
p = 0.003, unpublished, Table 5.7.2). When the deficiencies of C4A and C4B 
were assessed individually, C4A deficiency seemed to account for the difference 
observed in patients with the NTM vs the MTB (13/50 [26%] vs 2/31 [6%], OR 
5.095 95%CI=1.06- 24.39, p = 0.028, respectively, unpublished, Table 5.7.2). In 
contrast, there was no statistically significant difference in the frequency of the 
C4B deficiency.
As the majority of the NTM patients were female, C4 deficiencies were assessed 
in females only. The females in the healthy control group were compared with 
females in the NTM patient group, but not in the MTB group due to low female 
number in the MTB patient group (Study IV, Table 3). Female NTM patients had 
more frequent C4 deficiencies compared to controls (29/36 [81%] vs 55/100 [55%], 
OR = 3.39, 95% CI = 1.358–8.460, p = 0.007, Study IV). This difference in C4 
deficiency was especially seen in C4B deficiency (20/36 [56%] female NTM patients 
vs 38/100 [38%] in female controls, p = 0.027, respectively, Study IV Table 3). No 
difference was seen between female NTM and control patients in the frequency of 
C4A deficiency. 
Table 5.7.2. The C4 deficiencies in patients with nontuberculous mycobacteria (NTM), Mycobacterium 
tuberculosis (MTB) and in healthy control population (H). The data is only partly publsihed in Stady IV. 
Values are expressed as no. (%) of patients, unless otherwise stated.
NTM
n=50
MTBd
n=31
H
n=149 NTM vs MTB
d NTM vs H
Type of 
deficiency no. (%) no. (%) no. (%)
OR 
(95 % CI) p 
a OR a  
(95 % CI) p 
a
C4A <2 13 (26) 2 b (6) 24 (16) 5.095  (1.06–24.39) 0.028
1.83  
(0.85–3.95) 0.120
C4B <2 25 (50) 10 (32) 61 (41) 2.100  (0.824–5.350) 0.117
1.44  
(0.76–2.75) 0.263
C4A or C4B < 2 36c (72) 11 (35) 83 (56) 4.071  (1.574–10.533) 0.003
2.05  
(1.019–4.105) 0.042
C4 < 4 22 (44) 5 (16) 56 (38) 4.086  (1.35–12.37) 0.010
1.31  
(0.85–1.47) 0.421
OR = odds ratio.
CI= confidence interval
a p values for differences between groups.
b CT insertion is deleted.
c Two patients had both C4A <2 and C4B<2 deficiency, one patient had a total C4A deficiency 
d Unpublished MTB patients
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In the phenotype frequencies of the C4 allotypes, the A3, Q0 allotype was found in 
12/50 (24%) of the NTM patients but in only 2/31 (6%) of the MTB patients (p = 
0.042), which reflected the increased frequency of C4A deficiency in NTM patients 
(Table 5.7.3) (Table 4). We observed that the C4 allotype, A3, 3 was less common in 
the NTM patients (11/50, 22%) as compared to the healthy controls (58/149 [39%], 
p = 0.030, Study IV, Table 5) but not different from the MTB patients (data not 
shown). The allotype B1, 2 was found in only 6% of the NTM patients whereas it 
was seen in 20% of the healthy controls (p = 0.020, Study IV, Table 5). 
Table 5.7.3. The most common C4 phenotypes in patients infected with a nontuberculous mycobacteria 
(NTM), Mycobacterium tuberculosis (MTB) and Healthy group (H). The data has only been partly published 
in Stady IV.
NTM=50 a MTBe n=31a Total
e 
n=81a p 
b H n= 149 p b
no. (%) no. (%) no. (%) no. (%)
C4A phenotype c
3 12 (24) 2 (6) 14 (17) 0.042 21 (14) 0.103
3,2 3 n (6) 1 (3) 4 (5) 1.000 d 9 (6) 1.000 d
3,3 11 (22) 11 (35) 22 (27) 0.185 58 (39) 0.030
3,3,2 8 (16) 6 (19) 14 (17) 0.698 18 (12) 0.477
3,3,3 7 (14) 6 (19) 13 (16) 0.547 d 17 (11) 0.626
C4B phenotype
0 6 (12) 2 (6) 8 (10) 0.704 d 15 (10) 0.700
1 15 (30) 7 (23) 22 (27) 0.466 37 (25) 0.464
1,1 16 (32) 11 (35) 27 (33) 0.746 52 (35) 0.708
1,2 3 (6) 2 (6) 5 (6) 1.000 d 30 (20) 0.020
1,3 2 (4) 3 (10) 5 (6) 0.366 d 3 (2) 0.601d
2 3 (6) 1 (3) 4 (5) 1.000 d 6 (4) 0.694 d
2,2 0 (0) 2 (6) 2 (3) 0.144 d 5 (3) 0.333 d
a Values are expressed as no. (%) of patients with valid information unless otherwise stated.
b p Chi-squared test 
c One patient with C4A total deficiency
d Fisher’s exact test.
e Unpublished MTB patients
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Results 
A C4 deficiency (C4A or C4B deficiency) was found in 31/44 (70%) of the NTM 
patients with pulmonary infection and in 22/29 (76%) of those pulmonary 
NTM patients who met all ATS 2007 criteria. C4B deficiency was observed in 
all five patients with a cutaneous NTM infection fulfilling the ATS 2007 criteria. 
Interestingly, 67% of patients, who did not fulfill the radiological criteria but who 
gave several positive NTM sputum culture samples, had a C4 deficiency.
5.7.3 IMMUNOGLOBULIN CONCENTRATIONS AND OTHER LABORATORY 
MEASUREMENTS
Nobody had a low IgA concentration. The number of patients with low IgG and IgM 
levels was too low for statistical comparison (data not shown). The NTM patients had 
slightly lower plasma C3 concentrations compared with the MTB patient group. The 
CH100 was slightly higher in the NTM patients than in the MTB patients (data not 
shown). Serum C-reactive protein (CRP) levels, reviewed at the time of recruitment 
or closest +/- 6 months were significantly lower in the NTM patients than in the 
MTB patients (median [IQR] 6.50 [16%] vs 28.0 mg/l [46%], respectively, p = 
0.008). In contrast, no difference in erythrocyte sedimentation rate was observed 
between groups.
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6 DISCUSSION 
6.1 GENERAL DISCUSSION
We evaluated clinical and immunological findings in Finnish NTM patients. The 
strength of this study is due to its material; samples for mycobacterial cultures 
were analyzed in the same microbiological laboratory by the Central Microbiology 
Laboratory of Helsinki City, later Helsinki University Central Hospital Laboratory 
(HUSLAB). All data relevant to NTM infection was collected carefully from patient 
records. The NTM patient population was homogenous and there were no cases 
with a family history of a mycobacterial infection. The median (min-max) follow-up 
time of these patients was 7.0 years. By using this method we were able to form an 
opinion of clinical symptoms and signs, whereas previous studies have consisted 
of mostly nationwide registers without clinical findings of patients’ symptoms. 
Moreover, a statistician was included to the study group and statistical approaches 
were considered.
Both non-smoking and smoking patients revealed new information about NTM 
infections. Symptom onset commenced within a year before the first isolation of 
NTM, which revealed that the course of NTM disease may actually be quick. MAC 
pulmonary disease and bronchiectasis were more common among non-smoking 
elderly women without underlying pulmonary diseases compared to smokers. No 
significant association was found between smoking and high mortality, instead, 
severe underlying diseases were the most important predictors of mortality. 
We evaluated the “gold standard” ATS 2007 criteria for the first time. Many 
patients with NTM infection fail to meet the criteria. Obviously categorical methods 
are also leading to insufficient diagnosis of pulmonary NTM. Thus, the ATS 2007 
criteria seemed to be a weak prognostic factor. Namely, patients with MAC had 
three-times-longer survival than patients with other NTM.
The clinical signs suggested immunological deficiency. Therefore we investigated 
the association between NTM infections and complement C4 deficiency, which has 
not been studied previously. We found complement C4 deficiency to be a plausible 
risk factor for NTM infection.
A weakness of this study includes small patient numbers, which may cause bias 
and therefore larger studies to confirm the current findings are obviously required. 
Nonetheless, the results of this study are generalizable only to other areas in Finland 
or in Scandinavia. This study might assist clinicians and students in infectious and 
lung departments with NTM-disease patients, because these patients regularly visit 
the clinics and require intensive healthcare and frequent hospitalizations.
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To find NTM-infection patients for timely diagnosis, ATS 2007 criteria alone are 
insufficient. Namely, patients with NTM other than MAC have a poor prognosis. 
Smoking alone as a risk factor fails to account for poor prognosis. Moreover, those 
NTM patients without risk factors seemed to have a local immunodeficiency. 
Patients with NTM infections are in need of multi-center studies, where timely 
clinical symptoms and signs, as well as microbiological findings, are observed in 
proportion to radiological findings. We demonstrated that preliminary treatment 
with the anti-mycobacterial agents had no impact on prognosis. Therefore, treatment 
of NTM infections requires deeper insight, where severe underlying diseases and 
local immunological defects will be taken into consideration.
6.2 RISK FACTORS FOR NTM INFECTION 
6.2.1 SMOKING AS A RISK FACTOR FOR NTM INFECTION
The smoking group had more smoking-related lung diseases like COPD and also 
more other serious underlying diseases than non-smokers. In this study, life-time 
smoking abstinence was a requirement for non-smokers status. In fact, altogether 
more than half of smokers in this study had smoked for longer than 30 years and 
only one fifth had smoked for less than 10 years. This suggests that long-lasting 
smoking seems to be at least a contributing factor for NTM infection as suggested 
also in other studies (Sonnenberg et al. 2000, Maliwan et al. 2005, Varadi and 
Marras 2009).
Smoking with COPD, pneumoconiosis, bronchiectasis, prior tuberculosis, 
alcoholism or pulmonary alveolar proteinosis have been classified as risk factors 
for pulmonary MAC infection (Falkinham 1996). Although, smoking related diseases 
and other pulmonary diseases are well recognized risk factors for NTM infection, 
the data on the effect of smoking itself on the risk of acquiring a NTM infection is 
scarce and may be biased by the fact that in many studies previous smokers have 
been regarded as non-smokers (Prince et al. 1989, Kubo et al. 1998, Huang et al. 
1999). COPD with inhaled corticosteroid therapy was found to be strong risk factor 
for NTM pulmonary disease even in a recent study (Andréjak et al. 2013). 
Smoking may not be the main underlying factor for pulmonary NTM infections, 
however, because less than half of all NTM patients had never smoked. This is 
consistent with another patient cohort where 68% of the patients with NTM were 
lifetime non-smokers (Kim et al. 2008). Non-smokers also had less often previous 
pulmonary diseases. More than fourth quarter of non-smokers in our study and less 
than half of patients in a previous study showed no previous pulmonary diseases 
(Prince et al. 1989, Kubo et al.1998, Huang et al. 1999, Henry et al. 2004 Kim et al. 
2008). The most common pre-existing pulmonary disease among non-smokers was 
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bronchiectasis which was found in more than a quarter of them but very rarely of 
smokers. Bronchiectasis has been found more often in non-smoking female patients 
with chronic obstructive lung disease (Wittram et al. 2002, Wickremasinghe et 
al. 2005). Non-smokers also had serious underlying diseases less often and 
their infection was more often due to MAC than other NTM species. MAC has 
also been observed more often in previously healthy persons (Kubo et al. 1998, 
Huang et al. 1999, Field et al. 2004). These differences suggest that NTM infection 
among smokers and non-smokers might often be different in pathogenesis and 
underlying factors. However, no difference in symptom duration, occurrence of 
various symptoms, or other clinical parameters were seen except some more peculiar 
differences which might also point out the differences in infection between smokers 
and non-smokers. Non-smokers had a tendency for lower BMI and they had higher 
serum CRP and alkaline phosphatase levels. Non-smokers also presented a three 
fold higher incidence of nodular findings when compared to smokers.
Interestingly, there was a striking gender difference in relation to smoking status. 
Namely, men constitute majority of smokers, but less than a quarter of non-smokers. 
Also according to recent national statistics 77% of never smokers are women among 
persons over 65 years-of-age and the corresponding figures for people between 45–
64 years were 37% males (Varis and Virtanen 2013). In conclusion, smoking related 
pulmonary diseases predispose men for NTM infection and seems to shorten their 
survival. Smokers with COPD and severe underlying diseases are included to the 
other NTM group, which had significantly shorter median survival than MAC group.
6.2.2 AGE AND GENDER AS RISK FACTORS FOR NTM INFECTION
Pulmonary NTM infections are encountered in middle-aged or older adults. The 
mean age of all patients with NTM infection was 66.0 years. There were only 12 
patients that were under 50 years-of-age and had a pulmonary NTM isolation. 
There is no data whether the occurrence of NTM infections in middle-aged or 
older is due to local pulmonary changes or immunological factors, but younger 
individuals seem to be largely protected from NTM infection. However, host defense 
and immunological aging have been suggested as a predisposing reason for NTM 
infection (Beerman et al. 2010).
NTM isolations were quite evenly distributed between males and females 
when all NTM isolations were reviewed. Nonetheless, a majority of patients with 
MAC were female and a majority of MAC patients in this study had no underlying 
pulmonary diseases. The striking female predominance among healthy patients 
with a NTM infection has also puzzled researchers in many previous studies 
where female proportion has ranged from 21% up to 95% of all patients (Prince 
76
Discussion 
et al. 1989, Reich and Johnson 1991, Huang et al 1999, Kim et al. 2008). Elderly 
females have long been recognized as a risk group for pulmonary MAC infection for 
unknown reasons (Prince et al. 1989, Huang et al. 1999, Guide and Holland 2002, 
Kim et al. 2008). Moreover, elderly, slender female patients with NTM infection 
have often had bronchiectasis (Kim et al. 2008, Piersimoni and Scarparo 2008). 
Bronchiectasis and nodules were more common in ATS-positive as compared to 
ATS-negative patients. The classical patterns of the NTM disease with cavitary 
disease in middle-aged smoking men and fibronodular disease in elderly, non-
smoking women were uncommon both in our patient material and in other recent 
reports (Prince et al. 1989, Kubo et al. 1998, Dailloux et al. 2006, Piersimoni and 
Scarparo 2008). Although, the reason for this female predominance with a specific 
clinical morphotype is unclear, it has been suggested that females with pulmonary 
NTM might form a specific group with as yet undefined predisposing factors (Guide 
and Holland 2002, Taiwo and Glassroth 2010).
In conclusion, the men with NTM other than MAC, and who reported severe 
smoking-related diseases more frequently, had poor outcome. These gender and 
age findings are consistent with recent studies, in which M. kansasii pulmonary 
infection was found in two third of cases among middle age smoking males with 
COPD and who had 11% mortality within 40 years (Maliwan et al. 2005). Equally, 
M. xenopi pulmonary infection was found in two thirds of cases among smoking 
males with COPD (van Ingen et al. 2008) and M. malmoense pulmonary infection 
in two thirds of cases among middle-aged males with 13–15% mortality (Hoefsloot et 
al. 2009). In a retrospective cohort study of 124 patients, the majority was smoking 
males with M. malmoense or M. xenopi pulmonary infection which was related in a 
quarter of observed mortalities (Commans et al. 2014). Also, in a large register-based 
Danish study, male patients had worse outcome than females and M. malmoense 
and M. xenopi pulmonary infections were related to half of mortality as compared 
to infections due to other NTM species (Andréjak et al. 2010).
6.2.3 PREVIOUS PULMONARY DISEASES AS A RISK FACTOR FOR NTM 
INFECTION
In this study, two thirds of patients in both MAC and other NTM groups had a 
previous pulmonary disease which also points out those NTM infections are mainly 
seen in patients with at least some degree of previous pulmonary pathology. COPD 
was also the most common previous pulmonary disease and it was observed in a 
quarter of all patients. A quarter of patients, however, had no previous pulmonary 
diseases. Asthma was diagnosed in less than a quarter of patients, and together with 
COPD it explains the use of corticosteroids which was observed with systemic dosing 
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in one quarter and by inhalation in one fifth of patients. Pre-existing lung diseases, 
such as chronic bronchitis with emphysema or bronchiectasis have been traditionally 
related to pulmonary NTM infections (Field and Cowie 2004, Wickremasinghe et al. 
2005, Piersimoni and Scarparo 2008). Even in the latest large Danish population 
based-study, COPD was strongly linked to pulmonary NTM infection (Andréjak 
et al. 2013).
Bronchiectasis was the second most common pulmonary disease seen at the 
time of diagnosis. Both bronchiectasis and nodules were found for the most part in 
the non-smoking group and in ATS-positive patients. Further, bronchiectasis were 
concentrated to MAC group who had suffered from symptoms of NTM disease for 
longer and who also had longer mean survival time than patients with other NTM 
species. These facts would comply for the impression that MAC would be a slowly 
progressive process and bronchiectasis would be formed during it (Huang et al. 1999, 
Barker 2002, Griffith 2010). It seems unclear, however, whether bronchiectasis is 
a cause of NTM disease or a predisposing factor. This is substantiated by findings 
in this study where two thirds of non-smokers were female and over two thirds of 
non-smokers had experienced symptoms for less than 2 years, and yet bronchiectasis 
was observed in more than one fifth of them.
In line with previous studies one fifth of patients had a prior history of pulmonary 
tuberculosis (Dailloux et al. 2006, Varadi and Marras 2009, Billinger et al. 2009, 
Winthrop et al. 2010, Ito et al. 2015). Higher prevalence of tuberculosis has been 
reported in African gold miners with M. kansasii and MAC infection with half of 
prior pulmonary tuberculosis cases (Sonnenberg et al. 2000). Structural deformities 
like scoliosis or pectus excavatum have previously been linked to NTM infection but 
they were rare in this study (Guide and Holland 2002). In conclusion, bronchiectasis 
was concentrated to the MAC group, and related to longer survival compared to 
other NTM group. This suggests that bronchiectasis in MAC patients is a slowly 
progressive disease, which is in line with other studies (Huang et al. 1999, Barker 
2002, Griffith 2010). In contrast, COPD, prior tuberculosis, malignancies and other 
pulmonary diseases included to severe underlying diseases and concentrated to 
smokers, to ATS 2007 negative patients and to other NTM group with short survival. 
These findings should be taken into account in diagnosing and in the treatment 
of NTM patients.
6.2.4 SEVERE UNDERLYING DISEASES AS RISK FACTORS FOR NTM INFECTION
In this study, the classification of McCabe and Jackson (McCabe and Jackson 1962) 
was used mainly to be able to analyze the importance of diseases with potential lethal 
outcome on prognosis. Severe underlying diseases classified either as ultimately or 
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rapidly fatal were quite common and were observed in one third of patients. The 
severe underlying diseases were more common in half of the patients with other 
NTM as compared to one fifth of MAC isolations, in half of smokers as compared 
to one fifth of non-smokers, and in ATS-2007-criteria-negative patients (41 %) 
as compared to ATS-positive patients (23 %). These figures seem to be quite 
comparable to those observed with another classification, Charlson comorbidity 
index, in the study by Andréjak et al. (2010). They found that 17% of patients had 
a high Charlson comorbidity index and 40–50% had a medium index. Hayashi et al 
(2012) found comorbidities in 66.4% of patients and they observed in a multivariate 
model that both systemic (40%) and respiratory (38%) comorbidities were negative 
prognostic factors for all-cause mortality in HIV–negative patients with MAC lung 
disease. Various other underlying diseases have been observed to be common in 
NTM infected patients (Skogberg et al. 1995, Kim et al. 2008, Billinger et al. 2009, 
Lai et al. 2011, Yeha et al. 2014, Mirsaeidia et al. 2015, Gommans et al. 2015, Ito 
et al. 2015). Recently, malignant diseases and immunosuppressive conditions have 
been increasingly taken up as underlying factors for local or even disseminated 
NTM infection (Cordonnier et al. 2004, Doucette and Fishman 2004, Sexton et 
al. 2008, O`Connel et al. 2012, Browne et al. 2012, Al-Anazi et al. 2014, Gommans 
et al. 2015). A malignant disease was observed in less than one fifth of patients in 
this study and rare patients had immunosuppressive therapy, suggesting that these 
factors would not have common underlying factors for pulmonary NTM infection. 
Pulmonary, gastroenteric, and hematological malignancies are those most often 
related to NTM infection (Lai et al. 2102). At the highest end of immunosuppression, 
pulmonary NTM infections seem uncommon. The incidence of pulmonary NTM 
infection among stem-cell-transplant recipients between 2004 and 2013 was low 
(0, 95%) (Kang et al. 2015). In the USA, it has been observed that patients with 
rheumatoid arthritis have increased risk for NTM infections (Winthrop et al. 2013). 
In a large study on 29,131 rheumatoid arthritis patients they reported a 4.2 fold 
greater risk for NTM infection than non-rheumatoid patients (Yehb et al. 2014). 
Among peritoneal-dialysis patients, NTM peritonitis has been reported recently 
(Song et al.2012, Miyashita et al. 2014).
6.2.5 C4 DEFICIENCY AS A RISK FACTOR FOR NTM INFECTION 
This study suggested that C4 complement deficiency might be a risk factor for 
NTM infection. We observed that the deficiencies of C4 in the majority of NTM-
infected patients were significantly more common than in one third of the MTB 
patients or in more than half of the healthy controls. Especially, C4A deficiency 
was observed to be more common in the NTM patients than in the MTB group. 
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Further, our study suggested that C4 susceptibility might be a risk factor for NTM 
infection in a specific patient group of elderly female patients of whom 81% had a C4 
deficiency. However, this data must be viewed in light of the fact that complement 
C4 deficiencies are common in the Finnish population; 17% lack one of the two 
C4A alleles and 38% lack one of the two C4B alleles (Seppänen et al. 2006). Equal 
frequencies have been observed in European decent North Americans, of whom 
13% had a deficiency one of the two C4A alleles and 18% lacked one of the two C4B 
alleles (Blanchong et al. 2000).
This study was the first to suggest that complement C4 deficiencies might have 
some role in NTM infections. C4A deficiency has previously been linked to increased 
tendency to upper respiratory infections and various autoimmune diseases but also 
to pulmonary tuberculosis (Seppänen et al. 2006, Singh et al. 2007, Senbagavalli 
et al. 2011, Kainulainen et al. 2012). In contrast, C4B deficiency has been reported 
to have an association to another mycobacterial disease; leprosy (Messias et al. 
1993). Furthermore, pulmonary tuberculosis has been associated to HLA class 
I and II genes in several populations (Yuliwulandar et al. 2010, Shi et al. 2011, 
Dubaniewicz et al. 2000 Sriram et al. 2001, Lombard et al. 2006). The susceptibility 
to Mycobacterium tuberculosis (MTB) disease has been found to be variable among 
different ethnic groups although in real life the strength of exposure to it may play a 
big role of unknown reason respiratory infections (Dubaniewicz et al. 2000, Sriram 
et al. 2001). Together this data suggests that genetic defects or factors may play a 
role in who will get a mycobacterial infection. Today, only the background of genetic 
defects of rare disseminated NTM infections have been clarified in some patients. 
Genetic defects in them have been characterized in T-cell mediated immunity and 
in cytokine signaling in families with a few mutations in IFN-γ and IL-12 signaling 
(Dorman and Holland 2000, Holland 2001, Casanova and Abel 2002, Guide and 
Holland 2002, Haverkamp et al. 2006, Fernando and Britton 2006). The detailed 
genetic background of pulmonary NTM infections still waits to be solved. In recent 
studies, up to two-thirds of NTM infections were found in female patients without 
predisposing lung diseases (Cassidy et al. 2009, Thomson 2010, Iseman and Marras 
2008). The reason behind this female predominance has been hypothesized to be 
immunological defects making them more susceptible for NTM infections (Guide 
and Holland 2002). This study revealed that sufferers of one immunological defect, 
namely 81% of them, had a deficiency in C4 genes. Another distinct feature in this 
female group of patients is their well characterized high frequency of bronchiectasis 
(Field and Cowie 2004, Piersimoni and Scarparo 2008, Kim et al. 2008). 
Although, the exact link between C4 deficiency and mycobacterial infections 
is not verified, some data support a link between them. The polymorphisms of 
the complement and its receptor genes have been associated with pulmonary 
tuberculosis (Fernando and Britton 2006). It has been suggested, that complement 
80
Discussion 
proteins are involved in a mechanism through which mycobacteria enter the cell 
and may thereby evade the adaptive immune response (Gupta et al. 2012). The 
C4 deficiency found might partly prevent the complement activation and thus 
hamper the opsonization mechanisms and the positive feedback of IL-12/ IFN-γ 
in macrophages. The influence of aging may hamper the immune system, which 
might slow the manifest in both cellular and humoral immune responses. Those 
changes might predispose postmenopausal women to autoimmune diseases and 
NTM infections (Gameiro 2010, Kartalilja et al. 2013). Further, it has been suggested 
that while the immune system is getting older, hematopoietic stem cells have age-
dependent functional alterations and the aged hematopoietic system might not be 
able to return to normal capacity after stress or injury (Beerman et al. 2010). In 
conclusion we observed that a majority of NTM patients with bronchiectasis fulfilling 
ATS criteria, mostly women, had a deficiency in C4. Although the pathogenetic link 
has not been revealed, this suggests that C4 deficiency together with bronchiectasis 
might be indicative of the immunologic defect in pulmonary NTM infections of 
elderly females.
6.3 PROGNOSTIC FACTORS IN NTM INFECTIONS 
6.3.1 SMOKING AS A PROGNOSTIC FACTOR 
More than half of our patients were smokers and they had significantly higher 
mortality and shorter median survival time as compared to non-smokers. In a study 
from the USA, the immediate death causes of 2,990 people with NTM infection 
were reviewed (Mirsaedi et al. 2014). In this analysis from the USA, deceased NTM 
infected patients were 2.5 fold more likely to have COPD, 3.7 fold more likely to 
have bronchiectasis, 1.63 fold more likely to have interstitial lung disease and twice 
as common tobacco use as compared to deceased patients with tuberculosis. COPD 
was found to increase the risk of mortality in NTM patients already in an earlier 
study where as high as 55% mortality within 2 years of diagnosis 1995–1999 among 
COPD patients was reported (Henry et al. 2004). Less than half of the smokers 
had a diagnosis of COPD. The smokers also experienced severe underlying diseases 
more often, but mortality of the smokers did not differ from that of non-smokers. 
This suggests that at least in some smokers, the infection might be different from 
that of non-smokers, which is further supported by the lower frequency of MAC 
among the smokers as compared to non-smokers. Yet, severe underlying diseases 
could not be the main explanation of fatal outcome as two thirds of patients had 
no severe underlying diseases. The interplay of NTM infection and smoking-related 
COPD might be more complicated as it has also been suggested that NTM infection 
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might be one reason for rapid decline in pulmonary function in COPD disease 
(Huang et al. 2012). 
Less than half of patients were non-smokers and they did not differ from smokers 
in their clinical picture or in laboratory abnormalities, but in only a few points. 
Smokers had more often severe underlying diseases, higher serum CRP, and alkaline 
phosphatase levels and, unexpectedly, lower incidence of bronchiectasis. Lower 
incidence of bronchiectasis is in contrast with that previously reported among 
smokers. One of the classical forms of NTM-infections has been described as a 
tuberculosis-like fibrocavitary pattern of disease which often affects older male 
smokers with COPD, bronchiectasis, pneumoconiosis, or prior tuberculosis and 
has been associated to M. kansasii, M. xenopi, M.malmoense, and M. abscessus 
(Corbetta et al. 1999, The Research Committee of the British Thoracic Society 
2003, Arend et al. 2004, Hoefsloot et al. 2009, Varadi and Marras 2009, Andréjak 
et al. 2010). The other is a pattern of nodular bronchiectasis with or without 
fibrocavitary pulmonary changes and has been described mainly in connection 
to MAC infection and they have been found classically in middle-aged or older 
women who had never smoked (Wickremasinghe 2005, Glassroth 2008, Taiwo 
and Glassroth 2010). Prognosis in nodular form has been described as better than 
in fibrocavitary disease (Field et al. 2004, Waller et al. 2006, Huang et al. 1999, 
Taiwo and Glassroth 2010). These classical disease forms were not clearly evident 
in our patient population although the division according to smoking status would 
suggest it. Nodules were an infrequent finding and they were observed only in one 
third of non-smokers and rarely of smokers. However, MAC was a significantly 
more common finding among non-smokers than smokers. Bronchiectasis was more 
common in non-smokers than in smokers. Bronchiectasis has been associated to 
poor outcome (Field and Cowie 2006, Kim et al. 2008, Hyashi et al. 2012, Mirsaeidi 
2013). Either the low prevalence of bronchiectasis in our non-smokers or the early 
assessment of their presence at the time of positive NTM culture made it seem 
that they failed to affect the outcome of non-smokers. In conclusion, smokers had 
significantly higher mortality and shorter median survival time as compared to 
non-smokers. 
6.3.2 ATS CRITERIA AS A PROGNOSTIC FACTOR
ATS criteria were designed to help the clinician in treatment decisions and to guide 
which patients might benefit from antimycobacterial treatment (Griffith et al. 2007). 
Their prognostic value was not evaluated here. When all NTM isolations in HIV-
negative patients during the study period were collected, only half of the patients 
with a NTM isolation fulfilled the ATS criteria and this is line with other studies 
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(Bodle et al. 2008, Billinger et al. 2009). When ATS-positive and -negative patients 
were compared, ATS criteria fulfillment was not a clear predictor of mortality. The 
median survival time of patients fulfilling the ATS criteria was not different from 
that of the ATS-negative patients. Similar results have also been obtained in a larger 
register-based study where half of the patients with a NTM isolation were classified 
as colonized, one fifth as having possibly a NTM disease, and quarter as having a 
definitive NTM disease and no difference was observed in five year outcome of the 
patients in these groups (Andréjak et al. 2010).
ATS criteria were designed with, especially, MAC infections in mind (Griffith 
et al. 2007). Interestingly, patients who met the ATS criteria had better prognosis 
as compared to ATS-negative patients, both in MAC and other NTM groups. ATS-
negative and -positive patients demonstrated no difference in most of the clinical 
signs or symptoms from each other. Nodules were slightly more common among 
ATS-positive patients (27%) as compared to ATS negative (9%), and the same 
was observed with fatigue (56 vs 37% of patients, respectively). Severe underlying 
diseases, male gender, and previous pulmonary diseases were more common in 
ATS-negative patients in our patient cohort and in some other studies (Andréjak 
et al. 2010, Hyashi et al. 2012). Presence of severe underlying diseases was a 
significant predictor of poor outcome in this study and in that of Andréjak et al 
(2010). In the latter study, male gender was also associated to higher mortality. 
This data suggests that more studies are needed to find clinical signs that might 
define patients at risk of poor outcome or in need of medication. Close follow-up 
of patients could be recommended and recently poor prognosis has been reported 
in patients with hemoptysis and consolidation in radiological imaging (Commans 
et al. 2015). Among ATS negative patients, 65% did not meet radiological criteria: 
most were COPD patients with positive NTM sputum findings with high mortality 
due to severe COPD. By using only ATS criteria 2007, these COPD patients can 
be overlooked. This suggests that the ATS criteria were a poor predictor of case-
fatality. This is consistent with recent study from Denmark, which revealed that 
colonized patients had almost as high mortality as patients with definitive NTM 
diseases (Andréjak et al. 2010).
6.3.3 NTM STRAIN AS A PROGNOSTIC FACTOR
MAC comprised more than half of all NTM isolations and RGM (M. fortuitum, 
M. chelonae, M. abscessus) were the most other NTM isolations consisting less 
than one fifth of all NTM isolations and M. malmoense almost less than one fifth 
(and the species distribution corresponded that observed in northern Europe 
previously) (Thompsen et al. 2002). In line with some other reports, we observed 
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that pulmonary MAC infection was associated with significantly better prognosis 
with a median survival time of 13.0 years as compared to patients with another 
pulmonary NTM infection with a median survival time of 4.6 years (Andréjak et 
al. 2010, Hyashi et al. 2012). Although our patient material did not allow detailed 
analysis across all the different species, no difference in mortality during the first 
three or five years was observed between RGM, M. gordonae, or M. malmoense. 
It is evident that the prognosis of NTM infection may depend on the NTM species, 
but the mortality rate in various studies has also been very variable. Overall 5-year 
mortality of patients with ATS-criteria positive MAC pulmonary infection was 24% 
and 10-year mortality was 47% (Hayashi et al. 2012). However, MAC-infection 
related mortality was estimated to be only 5.4% within 5 years and 15.7% within 
10 years. In another study, three year mortality of 33% and five year mortality 
of 40% was associated to MAC isolation (Andréjak et al. 2010). In contrast, M. 
kansasii pulmonary infection was reported to cause death only in 8% of patients 
(Maliwan et al. 2005). M. xenopi infection was reported to carry only 15% overall 
mortality but in another study, mortality of up to 69% was reported (Andréjak et 
al. 2009, Varadi and Marras, 2009). M. xenopi and M. malmoense isolations were 
associated with about 40% three year and 50% five year case fatality rates in one 
study, but only 13% mortality was reported in another study for M. malmoense 
(Hoefsloot et al. 2009). 
M. gordonae has commonly been regarded as a colonizer only (Piersimoni and 
Scarparo 2008), but symptomatic infections due to M. gordonae infection have 
also been reported recently in patients with immunosuppression or malignancies 
(Eckburg et al. 2000, Griffith et al. 2007, Pinho et al. 2009). Our patients with M. 
gordonae isolation also had a malignancy. However, the similar and poor prognosis 
associated with M. gordonae isolation suggests that it should not be overlooked. 
Severe underlying diseases were also one of the most important predictors 
of mortality in this analysis. Interestingly, among patients without any severe 
underlying diseases, the survival curves were almost identical in MAC and other 
NTM groups. Even in the group of patients who had severe underlying diseases, 
MAC patients seemed to have a better prognosis as compared to patients with other 
NTM. There were also other differences between MAC and other NTM patients in 
their clinical picture and underlying characteristics. Patients with MAC had lower 
BMI, were more often female and non-smokers, and had more bronchiectasis, 
factors which together may all have affected the survival. These findings are in 
context with those previously reported (Kim et al. 2008, Obayashi 1999, Chan and 
Iseman 2010, Mirsaeidi et al. 2013). Notably, in recent studies MAC patients with 
both bronchiectasis and low BMI had more rapid progression of their pulmonary 
disease and higher mortality (Hayashi et al. 2012, Mirsaeidi et al. 2013, Yamakawa 
et al. 2013). This data suggests that MAC and other NTM species might hit various 
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patient groups and apart from geographical differences the host differences should 
probably be looked for more carefully. Within the groups of each NTM species 
there might also be different subgroups of patients with variable underlying and 
prognostic factors. In a recent study from Japan, MAC pulmonary infection with 
fibrocavitary or nodulary-bronchiectatic radiographic changes had mortality of 41% 
in 5-years and 75% in 10-years, but the corresponding mortality rates for nodular 
or bronchiectatic disease forms were only 18% and 35%, respectively (Hayashi et 
al. 2012).
Less than half of patients have suffered from symptoms for less than a year 
and additional one third less than two years. NTM infections have generally been 
regarded as slowly progressing processes which this finding challenges (Rosenzweig 
1979, Prince et al.1989, Huang et al. 1999, Field and Cowie 2006, Griffths et al. 
2007, Kim et al. 2008, Piersimoni and Scarparo 2008). In previous studies which 
have reported the median time between the onset of symptoms and NTM isolation 
it has varied from 4 months up to five-six years (Prince et al. 1989, Huang et al. 
1999, Arend et al. 2004). Time from symptoms to NTM isolation was significantly 
longer among MAC patients than other NTM patients. Furthermore, MAC patients 
were significantly more likely to have fatigue and fever and also had a lower BMI, 
which would all together fit in a longer disease process. A rapid course of NTM 
infection is also indicated by the finding of appearance of respiratory failure within 
the first 6 months after NTM isolation, especially among COPD patients (Yeh et al. 
2014a). Furthermore, median survival of less than a year has been reported for M. 
xenopi and M. malmoense infections, both in apparently immunocompetent and 
in solid-organ transplanted patients (Gommans et al. 2015). These findings suggest 
that frequent follow up of patients with NTM isolation could be encouraged at least 
soon after microbiological results have been obtained, because the symptom onset 
revealed rather rapid disease course and therefore timely diagnosis and evaluation 
of the predictors of mortality are useful. Namely, pulmonary MAC patients with 
bronchiectasis associated with significantly better prognosis as compared to patients 
with another pulmonary NTM with severe underlying disease. 
In future perspectives, further investigation with a larger study to confirm the 
current immunological findings and finding the prognostic factors are obvious. 
Further data on the effect of treatment on outcome would be needed.
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7 SUMMARY AND CONCLUSIONS 
The main results of the present study were:
I Nearly half of patients with a NTM isolation had never smoked. MAC comprised a 
majority of isolates among non-smokers and 41% among smokers. Non-smokers 
were significantly more often females than smokers. Over 80% of non-smokers 
but only half of smokers had no potentially fatal underlying diseases. Smokers 
had higher risk of mortality than non-smokers, but no difference was observed 
after adjusting for underlying diseases. Smokers and non-smokers seemed to 
have different risk factors for NTM infection. Symptoms had started within 
a year of positive NTM isolation in nearly half of patients suggesting rapid 
development of symptoms. 
II We found that half of patients with a NTM isolation fulfilled the 2007 ATS 
criteria. ATS-positive cases were more often female and had less often fatal 
underlying diseases as compared to ATS-negative cases. No significant difference 
was seen in median survival time or symptoms between ATS-positive and 
-negative cases except in fatigue, which was more common in ATS-positive 
patients. ATS-criteria fulfillment was a weak prognostic marker. 
III MAC was isolated in half of cases and MAC patients were more often female 
and had more often bronchiectasis and less often fatal underlying diseases 
than patients with other NTM. There was no difference in ATS-2007-criteria 
fulfillment between MAC and other NTM patients. A higher proportion of other 
NTM patients had suffered from symptoms less than a year as compared to 
MAC patients. MAC patients had significantly lower risk of death and longer 
survival time than other NTM patients. Even after adjustment for underlying 
diseases, other NTM was still associated with poorer outcome than MAC. 
IV A majority of Finnish NTM patients had significantly more frequent C4 
deficiencies (C4A or C4B) as compared to unselected healthy control subjects 
and MTB. Especially, a majority of female NTM patients demonstrated more 
frequent C4 deficiencies as compared to female controls. The data suggest C4 
deficiency to be a plausible risk factor for NTM infection especially in aged 
female patients. 
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